ezetimibe has been researched along with Atherogenesis in 199 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 30 (15.08) | 29.6817 |
| 2010's | 103 (51.76) | 24.3611 |
| 2020's | 66 (33.17) | 2.80 |
| Authors | Studies |
|---|---|
| Broncel, M; Gorzelak-Pabiś, P; Niedzielski, M; Woźniak, E | 2 |
| Baratzadeh, F; Jamialahmadi, T; Reiner, Ž; Sahebkar, A; Santos, RD; Simental-Mendía, LE; Susekov, AV; Xu, S | 1 |
| Bacchin, ASF; Bianco, HT; Caixeta, A; Damasceno, NRT; Fonseca, FA; França, CN; Izar, MCO; Mello, APQ; Moreira, FT; Neto, AMF; Pinto, LCS; Póvoa, RMS | 1 |
| Bittner, VA; Brown, TM; Chen, L; Colantonio, LD; Exter, J; Farkouh, ME; Huang, L; Jackson, EA; Levitan, EB; McKinley, EC; Muntner, P; Orroth, KK; Reading, SR; Rosenson, RS; Safford, MM; Woodward, M | 1 |
| Brath, H; Drexel, H; Hemetsberger, M; Hoelzl, R; Ray, KK; Siostrzonek, P; Zweiker, R | 1 |
| Cheng, CY; Hsu, CY; Lee, JD; Lee, M; Ovbiagele, B; Wu, YL | 1 |
| Ah, YM; Choi, HD; Jeong, M | 1 |
| Altabas, V; Biloš, LSK | 1 |
| Adachi, H; Hakoshima, M; Katsuyama, H; Yanai, H | 1 |
| Jia, Y; Martinez, L; Sanchez, SZ; Wang, X; Xi, X; Xie, W; Zhao, Q | 1 |
| Atar, D; Langslet, G; Tonstad, S | 1 |
| Aronow, WS; Bandyopadhyay, D; Devanabanda, AR; Ghosh, RK; Gupta, M; Mamas, M; Ray, KK; Tummala, R | 1 |
| Calabrò, P; De Ferrari, GM; Filardi, PP; Indolfi, C; Romeo, F | 1 |
| Ahn, CM; Cho, YH; Choi, D; Heo, JH; Hong, BK; Hong, MK; Hong, SJ; Jang, Y; Kim, BK; Kim, JS; Ko, YG; Lee, SJ; Lee, YJ; Rha, SW; Yun, KH | 1 |
| Pedicino, D; Volpe, M | 1 |
| Alam, S; Ballantyne, CM; Bhatt, DL; Cannon, CP; de Lemos, JA; Gao, Q; Kosiborod, M; Mues, KE; Rosenson, RS; Shaik, A | 1 |
| Bress, AP; Brown, TM; Derington, CG; Exter, J; Herrick, JS; Jackson, EA; Muntner, P; Orroth, K; Poudel, B; Reading, S; Rosenson, RS; Safford, MM; Virani, SS; Woodward, M; Zheutlin, AR | 1 |
| Becker, C; Bilitou, A; Katzmann, JL; Laufs, U | 1 |
| Hu, YX; Jing, Q; Li, FF; Liang, C; Liang, YL; Qin, YW; You, HM; Zhao, XX; Zhu, RF | 1 |
| Kelsey, MD; Newby, LK | 1 |
| Baum, SJ; Bilitou, A; Gillard, KK; Louie, MJ; McQueen, RB; Nash, B; Ray, KK; Sasiela, WJ; Shah, H | 1 |
| Baum, SJ; Gaudet, D; Gencer, B; Kassahun, H; Knusel, B; Kuder, JF; Lepor, NE; López, JAG; Murphy, SA; O'Donoghue, ML; Ran, X; Rosenson, RS; Sabatine, MS; Stout, E; Wang, H; Wu, Y | 1 |
| Attipoe-Dorcoo, S; Jackson, SL; Loustalot, F; Park, S; Sekkarie, A; Sperling, L; Therrien, NL; Thompson-Paul, AM; Woodruff, RC; Yang, PK | 1 |
| Ahn, CM; Cho, JY; Cho, YH; Choi, D; Hong, MK; Hong, SJ; Im, SW; Jang, Y; Kang, WC; Kim, BK; Kim, JS; Ko, YG; Lee, SJ; Lee, SY; Lee, YH; Lee, YJ; Park, Y; Shin, WY; You, SC; Yun, KH | 1 |
| Calvert, SB; Cziraky, MJ; Eapen, Z; Granger, CB; Haynes, K; Nanna, MG; Nelson, AJ; Pagidipati, NJ; Shambhu, S | 1 |
| Stone, NJ | 1 |
| Broncel, M; Gorzelak-Pabiś, P; Niedzielski, M; Woźniak, A; Woźniak, E | 1 |
| Ako, J; Iekushi, K; Majewska, R; Mitani, H; Suzuki, K; Touzeni, S; Yamashita, S | 1 |
| Cha, JJ; Cho, JM; Hong, SJ; Joo, HJ; Kim, JH; Kim, JS; Kim, SY; Lee, CW; Lee, JY; Lee, K; Lee, PH; Lee, SW; Lim, DS; Lim, S; Lim, SY; Moon, JY; Na, JO; Park, JH; Park, JS; Yu, CW | 1 |
| Ahn, CM; Choi, D; Choi, HH; Choi, YJ; Heo, JH; Hong, MK; Hong, SJ; Hur, SH; Jang, Y; Kim, BK; Kim, JH; Kim, JS; Kim, KJ; Ko, YG; Lee, JH; Lee, SH; Lee, SJ; Lee, YJ; Park, KH | 1 |
| Bilz, S; Brändle, M; Laimer, M; Lehmann, R; Renström, F; Singeisen, H | 1 |
| Hong, YA; Kim, DW; Lee, K; Lee, M; Myong, JP; Park, MW | 1 |
| Di Costanzo, A; Esposito, G; Indolfi, C; Sorrentino, S; Spaccarotella, CAM | 1 |
| Ahn, CM; Cha, JJ; Cho, YH; Choi, D; Choi, S; Choi, WG; Hong, MK; Hong, SJ; Jang, Y; Jeong, JO; Kim, BK; Kim, JS; Ko, YG; Lee, SJ; Lee, WS; Lee, YJ; Park, W; Yoon, CH | 1 |
| Landmesser, U; Sinning, D | 1 |
| Bramlage, P; Brandts, J; Brix, JM; Danne, T; Heyer, CHJ; Holl, RW; Müller-Wieland, D; Tittel, SR; Zimny, S | 1 |
| Chen, Z; Jin, J; Li, D; Li, Y; Liu, L; Liu, X; Shan, L; Wang, M; Xu, T; Zhang, W | 1 |
| Corsini, A; Ferri, N; Ruscica, M; Santos, RD | 1 |
| Ahn, CM; Cho, YH; Choi, D; Heo, JH; Hong, BK; Hong, MK; Hong, SJ; Jang, Y; Kim, BG; Kim, BK; Kim, JS; Ko, YG; Lee, SJ; Lee, YJ; Rha, SW; You, SC; Yun, KH | 1 |
| Kim, HS; Kim, NH; Kim, SG; Kim, SS; Ko, SH; Lee, BK; Lee, I; Lee, JH; Moon, JS; Park, IR; Won, KC | 1 |
| Leong, D; Wu, PE | 1 |
| Arai, H; Arai, T; Harada, K; Hayashi, M; Imai, T; Ito, H; Katayama, Y; Kobayashi, T; Kuwabara, M; Nishida, H; Ohashi, Y; Oikawa, S; Otonari, T; Ouchi, Y; Rakugi, H; Sakabe, K; Sakuma, I; Sasaki, J; Tanaka, S; Uchida, Y; Urabe, T; Yamamoto, M; Yamashita, S; Yokota, N; Yokote, K | 1 |
| DiMario, S; Philip, K; Shen, X | 1 |
| Ballantyne, CM; Bhatt, DL; Cannon, CP; de Lemos, JA; Elliott-Davey, M; Kosiborod, MN; Liu, Y; Mues, KE; Rosenson, RS; Yazdi, D | 1 |
| Abtan, J; Amarenco, P; Béjot, Y; Bruckert, E; Cabrejo, L; Cha, JK; Charles, H; Ducrocq, G; Giroud, M; Guidoux, C; Hobeanu, C; Kim, JS; Kim, YJ; Labreuche, J; Lapergue, B; Lavallée, PC; Lee, BC; Lee, KB; Leys, D; Mahagne, MH; Meseguer, E; Nighoghossian, N; Pico, F; Samson, Y; Sibon, I; Steg, PG; Sung, SM; Touboul, PJ; Touzé, E; Varenne, O; Vicaut, É; Yelles, N | 1 |
| Cao, Z; Chen, X; Liu, G; Liu, J; Wang, B; Wang, J; Wang, Y; Wu, Y; Xian, X; Xu, MJ; Yang, C; Zhang, F | 1 |
| Ambrosio, G; Armstrong, PW; De Ferrari, GM; Green, JB; Holman, RR; Leonardi, S; Peterson, ED; Stevens, SR; Wamil, M | 1 |
| Ahmed, ST; Akeroyd, JM; Ballantyne, CM; Dixon, DL; Gluckman, TJ; Jia, X; Nambi, V; Petersen, LA; Ramsey, DJ; Rifai, MA; Stone, NJ; Virani, SS | 1 |
| Blom, DJ; Bouharati, C; Chilton, R; Ebrahim, IO; Karamchand, S; Leisegang, RF; Musa, MG; Naidoo, P; Raal, FJ; Rambiritch, V; Ranjith, N; Shunmoogam, N; Tonder, AV | 1 |
| Allahyari, A; Hagström, E; Jernberg, T; Leosdottir, M; Lundman, P; Ueda, P | 1 |
| Lütjohann, D; Sijbrands, E; Weingärtner, O | 1 |
| Kuwabara, M; Ouchi, Y; Saikawa, T; Sasaki, J | 1 |
| Cho, L | 1 |
| Bacalbasa, N; Bratu, OG; Crismaru, I; Diaconu, CC; Gaman, MA; Pantea Stoian, A; Stanescu, AMA | 1 |
| Bussmann, J; Van Eck, M; Verwilligen, RAF | 1 |
| Corsini, A; Ferri, N | 1 |
| Bangalore, S; Chaudhry, R; Costa, SP; Lyubarova, R; Mathew, RO; Rosenson, RS; Sidhu, MS | 1 |
| Al Matrooshi, NO; Aldhaleei, WA; Bhagavathula, AS; Rahmani, J | 1 |
| Goonasekera, MA; Haynes, RJ; Mafham, MM | 1 |
| Fras, Z; Mikhailidis, DP | 1 |
| Rached, F; Santos, RD | 1 |
| Dornstauder, E; Fraas, U; Katzmann, JL; Laufs, U; Smieszek, T; Sorio-Vilela, F; Zappacosta, S | 1 |
| Bobbert, T; Combes, G; Duparc, T; Genoux, A; Grenkowitz, T; Hollstein, T; Ingueneau, C; Kassner, U; Martinez, LO; Perret, B; Ruidavets, JB; Schumann, F; Steinhagen-Thiessen, E | 1 |
| Angeli, V; Azhar, SH; Balachander, A; Chew, HS; Koh, XH; Lim, HY; Lim, SY; Ng, LG; Phua, ML; See, WQ; Tan, C; Tan, Y; Tang, Y; Thiam, CH; Yeo, KP; Zhao, MH | 1 |
| Piszczatoski, C; Powell, J | 1 |
| Banach, M; Bunc, M; Dudek, D; Durak-Nalbantic, A; Dyrbus, K; Fedacko, J; Fras, Z; Gaita, D; Gierlotka, M; Jarai, Z; Magda, SL; Margetic, E; Margoczy, R; Ostadal, P; Pella, D; Penson, PE; Reiner, Ž; Trbusic, M; Udroiu, CA; Vlachopoulos, C; Vrablik, M; Vulic, D | 1 |
| Abdallah, R; Ali, AH; Ayoub, MA; Dakroub, A; Eid, AH; El-Yazbi, AF; Iratni, R; Orekhov, A; Shaer, F; Yassine, HM; Younis, N; Zibara, K | 1 |
| Arai, H; Bujo, H; Daida, H; Harada-Shiba, M; Ishibashi, S; Koga, N; Masuda, D; Oikawa, S; Yamashita, S | 1 |
| Ballantyne, CM; Beacham, LA; Miller, DL; Nicholls, SJ; Nissen, SE; Ray, KK; Riesmeyer, JS; Ruotolo, G | 1 |
| Borén, J; Bruckert, E; Catapano, AL; Chapman, MJ; Fazio, S; Ference, BA; Ginsberg, HN; Graham, I; Hegele, RA; Horton, JD; Krauss, RM; Landmesser, U; Laufs, U; Masana, L; Nicholls, SJ; Nordestgaard, BG; Packard, CJ; Raal, FJ; Ray, KK; Schunkert, H; Stock, JK; Taskinen, MR; Tokgözoglu, L; van de Sluis, B; Watts, GF; Wiklund, O | 1 |
| Ballantyne, CM; Baum, SJ; Howard, WB; Karayan, L; Knowles, JW; Myers, KD; Wilemon, KA | 1 |
| Cannon, CP; Genest, J; Gupta, M; Mancini, GBJ; Raggi, P; Ray, KK; Santos, RD; Tsigoulis, M; Watts, GF | 1 |
| Phan, YL; Spinler, SA; Waite, LH | 1 |
| Flugelman, MY; Halon, DA; Jubran, A; Lavie, G; Shapira, C; Zafrir, B | 1 |
| Lloyd-Jones, DM | 1 |
| Giugliano, RP; Sabatine, MS | 1 |
| Cannon, CP; Khan, I; Klimchak, AC; Reynolds, MR; Sanchez, RJ; Sasiela, WJ | 1 |
| El-Barbari, AA; El-Tamalawy, MM; Hassan, TM; Ibrahim, OM | 1 |
| Wójcik, C | 1 |
| Aggarwal, J; Boatman, B; Harrison, DJ; Menzin, J; Patel, JG; Stern, K; Yu, J | 1 |
| Beaubrun, A; Davis, K; Fox, KM; Inomata, H; Kajinami, K; Meyers, J; Nagar, SP; Qian, Y; Rane, PP | 1 |
| Antoku, Y; Egashira, K; Honda, K; Ichi, I; Koga, JI; Matoba, T; Nakano, K; Tsutsui, H | 1 |
| Boklage, SH; Elassal, J; Ghannam, AF; Gupta, R; Karalis, DG; Mallya, UG | 1 |
| Ahangari, N; Ghayour Mobarhan, M; Pasdar, A; Sahebkar, A | 1 |
| Fox, KM; Han, S; Kim, E; Kim, H; Kim, S; Qian, Y; Rane, PP; Suh, HS; Zhao, Z | 1 |
| Bujas-Bobanovic, M; Ganda, OP; Koren, A; Leiter, LA; Letierce, A; Mandel, J; Plutzky, J; Sanganalmath, SK | 1 |
| He, F; Li, T; Li, Z; Liu, X; Su, J; Wu, W; Xu, R; Yan, Y; Zhao, M | 1 |
| Brownrigg, J; Catterick, D; Danese, MD; Gleeson, M; Khunti, K; Kondapally Seshasai, SR; Kutikova, L; Ray, KK; Sorio-Vilela, F | 1 |
| Cannon, CP; Khan, I; Klimchak, AC; Reynolds, MR; Rosenson, RS; Sanchez, RJ; Sasiela, WJ | 1 |
| Banach, M; Corsini, A; Ruscica, M; Sahebkar, A; Sirtori, CR | 1 |
| Bucheit, JD; Dixon, DL; Kim, CJ; Pamulapati, LG; Pozen, J; Sisson, EM; Smith, SR; Wohlford, GF | 1 |
| Chan, P; Liu, Z; Ma, YB; Tomlinson, B; Zhang, Y | 1 |
| Al Rifai, M; Birnbaum, Y; Jia, X; Smith, SC; Virani, SS | 1 |
| Blumenthal, RS; Chuzi, S; Grundy, SM; Lloyd-Jones, DM; Pfenniger, A; Smith, SC; Stone, NJ; Virani, SS | 1 |
| Grundy, SM; Stone, NJ | 1 |
| Boettcher, A; Kramer, W; Liebisch, G; Orsó, E; Robenek, H; Schmitz, G; Wolf, Z | 1 |
| Komine, T; Mu, S; Suzuki, H; Takada, T; Tanaka, Y; Yamamoto, H; Yamanashi, Y | 1 |
| Bode, C; Clemens, A; Hehn, P; Hilgendorf, I; Kaier, K; Manhart, L; Merz, J; Peikert, A; Schäfer, I; Sheng, X; Stachon, P; von Zur Mühlen, C; Willecke, F; Wolf, D; Zehender, M; Zirlik, A | 1 |
| Cannon, CP; D'Agostino, RB; Khan, I; Klimchak, AC; Massaro, JM; Reynolds, MR; Sanchez, RJ; Sasiela, WJ | 1 |
| Shoji, T | 1 |
| Jones, PJ; Myrie, SB; Othman, RA | 1 |
| Ballantyne, CM; Cain, VA; Hoogeveen, RC; Karlson, BW; Palmer, MK; Raya, JL | 1 |
| Ben-Yehuda, O; Constance, C; Hanson, ME; Lin, J; Lowe, RS; Tershakovec, AM; Wenger, NK; Zieve, F | 1 |
| Iwasaka, T; Jo, F; Kubo, R; Kusabe, M; Morimoto, S; Morita, T; Nakahigashi, M; Nakano, C; Okuno, Y; Seo, M; Shiojima, I; Someya, K; Takahashi, N; Toyoda, N; Ueda, H | 1 |
| Chang, WT; Huang, SK; Liau, I; Yang, YC | 1 |
| Jackevicius, CA; Ko, DT; Krumholz, HM; Lu, L; Ross, JS; Tu, JV | 1 |
| Blanco-Vaca, F; Cedó, L; Escolà-Gil, JC; Julve, J; Martín-Campos, JM; Quesada, H | 1 |
| Cavasin, MA; Chonchol, M; Demos-Davies, KM; Jablonski, K; Keenan, AL; Kendrick, J; Levi, M; Masuda, M; Masuda, R; McKinsey, TA; Miyazaki, M; Miyazaki-Anzai, S; Saunders, SJ | 1 |
| Frazee, SG; Garavaglia, SB; Jackevicius, CA; Krumholz, HM; Levin, R; Novshadian, H; Ross, JS; Stettin, G | 1 |
| Camargo, LM; Ferreira, CE; Fonseca, FA; França, CN; Izar, MC; Roman, RM | 1 |
| Cui, CJ; Li, JJ; Li, S | 1 |
| Eguchi, Y; Fujita, K; Honda, Y; Hyogo, H; Imajo, K; Kessoku, T; Kirikoshi, H; Mawatari, H; Nakajima, A; Nozaki, Y; Ogawa, Y; Ono, M; Saito, S; Sumida, Y; Taguri, M; Tomeno, W; Wada, K; Yoneda, M | 1 |
| Adachi, H; Bekki, H; Honma, T; Nakano, H; Nakata, M; Nohara, M; Yamamoto, K; Yoshiyama, H | 1 |
| Angeli, V; Khoo, LH; Soh, SY; Thiam, CH | 1 |
| Ángeles-Garay, U; Carrillo-González, AL; Hernández, C; Jara, L; Medina, G; Olvera-Acevedo, A; Peralta-Amaro, AL; Vera-Lastra, OL | 1 |
| Golledge, J; Guerrero-Romero, F; Sahebkar, A; Simental-Mendía, LE; Watts, GF | 1 |
| Gao, K; Tie, C; Xie, X; Zhang, N | 1 |
| Gao, K; Shen, J; Tie, C; Wang, JA; Xie, X; Zhang, N; Zhang, S | 1 |
| Li, SX; Liao, DF; Liu, Z; Ni, YG; Qin, L; Yang, YB; Yang, YX; Zheng, XL; Zhu, N | 1 |
| Butler, CR; O'Hare, AM | 1 |
| Kobayashi, T; Kurozumi, A; Masuda, D; Mori, H; Okada, Y; Tanaka, Y; Yamashita, S | 1 |
| Calderón-Aranda, E; Cruz-Dominguez, MP; Jara, LJ; Medina, G; Méndez-Flores, S; Vera-Lastra, O | 1 |
| Bibbins-Domingo, K; Coxson, PG; Guzman, D; Kazi, DS; Moran, AE; Ollendorf, DA; Pearson, SD; Penko, J; Tice, JA | 1 |
| Chung, RT; Corey, KE; Giugliano, R; Simon, TG | 1 |
| DiNicolantonio, JJ; Lavie, CJ; O'Keefe, JH | 1 |
| Derosa, G; Dolezelova, E; Maffioli, P; Nachtigal, P; Sahebkar, A; Stein, E | 1 |
| Basurto, L; Hernández-Valencia, M; Manuel-Apolinar, L; Saucedo, R; Zárate, A | 1 |
| Blumenthal, RS; Musunuru, K | 1 |
| Davidson, M; Robinson, JG | 1 |
| Kohalmy, K; Monostory, K; Pascussi, JM; Rozman, D; Sárváry, E | 1 |
| Altmann, SW; Basso, F; Davis, HR; Hoos, LM; Lally, SM; Tetzloff, G | 1 |
| Hamilton-Craig, IR | 1 |
| Spence, JD | 1 |
| Hamilton, P | 1 |
| Pazianas, M | 1 |
| Böger, R; Eggeling, S; Meinertz, T; Munzel, T; Ostad, MA; Schwedhelm, E; Tschentscher, P; Warnholtz, A; Wenzel, P | 1 |
| Aragoncillo, P; Fernández-Cruz, A; Gómez-Garre, D; González-Rubio, ML; Granados, R; Muñoz-Pacheco, P | 1 |
| Almazan, F; Choi, SH; Crosier, P; Fang, L; Hall, C; Hansen, LF; Hartvigsen, K; Juliano, J; Klemke, RL; Miller, ER; Miller, YI; Pattison, J; Stoletov, K; Witztum, JL | 1 |
| Avis, HJ; Hutten, BA; Kastelein, JJ; Vissers, MN; Wijburg, FA | 1 |
| Al Badarin, FJ; Kopecky, SL; Kullo, IJ; Thomas, RJ | 1 |
| Inagaki, M; Ishigami, M; Masuda, D; Nakagawa-Toyama, Y; Nakatani, K; Nishida, M; Ohama, T; Sandoval, JC; Tsubakio-Yamamoto, K; Yamashita, S | 1 |
| Atrott, K; Bourayou, R; Dietrich, T; Fleck, E; Graf, K; Gräfe, M; Hucko, T; Jahnke, C; Klein, C; Paetsch, I; Schnackenburg, B; Stawowy, P | 1 |
| Tomkin, GH | 1 |
| Parhofer, K | 1 |
| Elisaf, M; Kalogirou, M; Tsimihodimos, V | 1 |
| Ferrario, CM | 1 |
| Devine, PJ; Griffen, L; Miller, M; Stanek, EJ; Taylor, AJ; Turco, M; Villines, TC; Weissman, NJ | 1 |
| Rizzoni, D; Rossi, GP | 1 |
| Mangat, R; Proctor, SD; Russell, JC; Uwiera, R; Vine, DF; Wang, Y; Warnakula, S | 1 |
| Boman, K; Brudi, P; Egstrup, K; Gohlke-Baerwolf, C; Holme, I; Kesäniemi, YA; Malbecq, W; Pedersen, TR; Rossebø, AB; Wachtell, K; Willenheimer, R | 1 |
| Howard, WJ | 1 |
| Betters, JL; Jia, L; Yu, L | 1 |
| Corsini, A; Poli, A | 1 |
| Montgomery, BD | 1 |
| Ahmed, MH; Byrne, CD | 1 |
| Ishibashi, T; Takeishi, Y | 1 |
| Izumi, T; Masuda, T; Takahira, N; Tojo, T; Yamaoka-Tojo, M | 1 |
| Morishita, R; Nakagami, H; Osako, MK | 1 |
| Ganotakis, ES; Lioudaki, E; Mikhailidis, DP | 1 |
| Yamaoka-Tojo, M | 1 |
| Krumholz, HM | 1 |
| Davidson, MH | 1 |
| Davis, HR; Lowe, RS; Neff, DR | 1 |
| Anderson, JD; Berr, SS; Chew, JD; Christopher, JM; DiMaria, JM; Epstein, FH; Hagspiel, KD; Harthun, NL; Hunter, JR; Kramer, CM; Meyer, CH; Wang, H; West, AM; Winberry, GB | 1 |
| Taylor, AJ | 1 |
| De Sutter, J; Descamps, OS; Guillaume, M; Missault, L | 1 |
| Justo, RN | 1 |
| Hoffmann, MM; Jacob, S; Konrad, T; Müller-Schewe, T; Winkler, K | 1 |
| Caccavello, R; Gugliucci, A; Kotani, K; Miyamoto, M; Sakane, N | 1 |
| Morinaga, Y; Nakazato, M; Shiiya, T; Tamaki, N; Ueno, H | 1 |
| Stanek, EJ; Taylor, AJ; Villines, TC | 1 |
| Green, D; McDonald, J; O'Riordan, E; Panayotova, R; Ritchie, JP | 1 |
| Stroes, ES; van der Valk, FM; van Wijk, DF | 1 |
| Darlington, JW; Gershkovich, P; Lee, SD; Wasan, KM | 1 |
| Chait, A; Ding, Y; Goodspeed, L; Han, CY; Kim, J; O'Brien, KD; Subramanian, S; Teresa, AS; Umemoto, T; Wang, S | 1 |
| Cachofeiro, V; Fernández-Cruz, A; Gómez-Garre, D; Miana, M; Muñoz-Pacheco, P; Ortega-Hernández, A | 1 |
| Kelder, T; Kleemann, R; Kooistra, T; Radonjic, M; van Ommen, B; Verschuren, L; Wielinga, PY | 1 |
| Keane, WF; Neff, DR; Tomassini, JE | 1 |
| Genser, B; März, W; Nestel, P; Silbernagel, G | 1 |
| Ahmedani, BK; Canepa Escaro, F; Divine, G; Gamalski, S; Hayek, S; Lanfear, DE; Pladevall, M; Sattar, A; Wells, KE; Williams, LK | 1 |
| Coakley, J; Forbes, DA; Martin, AC; Sullivan, DR; Watts, GF | 1 |
| Borthwick, F; Cheeseman, CI; Hassanali, Z; Mangat, R; Proctor, SD; Russell, JC; Uwiera, RR; Vine, DF; Warnakula, S | 1 |
| Michishita, I; Mizuguchi, I; Nozue, T; Sasaki, M; Tsunoda, T; Yamada, M | 1 |
| Chandalia, M; Jialal, I | 1 |
| Allen, C; Amabile, N; Barrios, V; Chen, JW; Johnson-Levonas, AO; Massaad, R; Paganelli, F; Vandormael, K | 1 |
| Feingold, KR; Moser, AH; Pan, XM; Rapp, JH; Staprans, I | 1 |
| Burnett, JR; Huff, MW | 1 |
| Balcerak, M; Broncel, M; Chojnowska-Jezierska, J | 1 |
| Vaverková, H | 1 |
| Devaraj, S; Jialal, I | 1 |
| Padial, LR | 1 |
| Greenland, P; Lloyd-Jones, D | 1 |
| Stein, EA | 1 |
| Suckling, K | 1 |
60 review(s) available for ezetimibe and Atherogenesis
| Article | Year |
|---|---|
The Effects of Statin Dose, Lipophilicity, and Combination of Statins plus Ezetimibe on Circulating Oxidized Low-Density Lipoprotein Levels: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Topics: Atherosclerosis; Cholesterol, LDL; Drug Therapy, Combination; Ezetimibe; Humans; Hydrophobic and Hydrophilic Interactions; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lipoproteins, LDL; Oxygen; Randomized Controlled Trials as Topic; Regression Analysis; Risk Factors; Treatment Outcome | 2021 |
Association Between Intensity of Low-Density Lipoprotein Cholesterol Reduction With Statin-Based Therapies and Secondary Stroke Prevention: A Meta-analysis of Randomized Clinical Trials.
Topics: Aged; Anticholesteremic Agents; Atherosclerosis; Cardiovascular Diseases; Cholesterol, LDL; Ezetimibe; Hemorrhagic Stroke; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Randomized Controlled Trials as Topic; Stroke | 2022 |
Comparative safety and efficacy of low- or moderate-intensity statin plus ezetimibe combination therapy and high-intensity statin monotherapy: A meta-analysis of randomized controlled studies.
Topics: Anticholesteremic Agents; Atherosclerosis; C-Reactive Protein; Drug Therapy, Combination; Dyslipidemias; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Treatment Outcome | 2022 |
The Role of Endothelial Progenitor Cells in Atherosclerosis and Impact of Anti-Lipemic Treatments on Endothelial Repair.
Topics: Anticholesteremic Agents; Atherosclerosis; Endothelial Progenitor Cells; Ezetimibe; Humans; Proprotein Convertase 9 | 2022 |
Molecular Biological and Clinical Understanding of the Statin Residual Cardiovascular Disease Risk and Peroxisome Proliferator-Activated Receptor Alpha Agonists and Ezetimibe for Its Treatment.
Topics: Atherosclerosis; Cardiovascular Diseases; Cholesterol; Cholesterol, HDL; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Insulin Resistance; Lipoproteins; PPAR alpha; Randomized Controlled Trials as Topic; Triglycerides | 2022 |
Do we need new lipid-lowering agents in the era of PCSK9 inhibitors? Recent advances.
Topics: Anticholesteremic Agents; Atherosclerosis; Cardiovascular Diseases; Cholesterol, LDL; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; PCSK9 Inhibitors; Proprotein Convertase 9 | 2022 |
Bempedoic acid and its role in contemporary management of hyperlipidemia in atherosclerosis.
Topics: Atherosclerosis; Cholesterol, LDL; Dicarboxylic Acids; Ezetimibe; Fatty Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents | 2022 |
[From statin revolution to gene silencing therapy: 50 years of evolution in the treatment of hypercholesterolemia].
Topics: Anticholesteremic Agents; Atherosclerosis; Cardiovascular Diseases; Cholesterol, LDL; Drug Therapy, Combination; Ezetimibe; Gene Silencing; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hyperlipidemias; Proprotein Convertase 9 | 2022 |
The Effects of Statins, Ezetimibe, PCSK9-Inhibitors, Inclisiran, and Icosapent Ethyl on Platelet Function.
Topics: Anticholesteremic Agents; Atherosclerosis; Cardiovascular Diseases; Cholesterol; Cholesterol, LDL; Eicosapentaenoic Acid; Ezetimibe; Fibrinolytic Agents; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertriglyceridemia; PCSK9 Inhibitors; Proprotein Convertase 9; Triglycerides | 2023 |
Fixed Combination for the Treatment of Dyslipidaemia.
Topics: Anticholesteremic Agents; Atherosclerosis; Cholesterol, LDL; Drug Therapy, Combination; Dyslipidemias; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Treatment Outcome | 2023 |
PCSK9 Inhibitors: From Nature's Lessons to Clinical Utility.
Topics: Animals; Atherosclerosis; Cardiovascular Diseases; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypolipidemic Agents; PCSK9 Inhibitors | 2020 |
Low-density lipoprotein cholesterol lowering treatment: the current approach.
Topics: Antibodies, Monoclonal, Humanized; Anticholesteremic Agents; Atherosclerosis; Benzimidazoles; Bile Acids and Salts; Carrier Proteins; Cholesterol, LDL; Dicarboxylic Acids; Europe; Ezetimibe; Fatty Acids; Gene Expression; Guidelines as Topic; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; PCSK9 Inhibitors; Proprotein Convertase 9; RNA, Small Interfering | 2020 |
Clinical Pharmacology of Statins: an Update.
Topics: Adolescent; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Atherosclerosis; Child; Cholesterol, LDL; Drug Therapy, Combination; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; PCSK9 Inhibitors; Primary Prevention; RNA, Small Interfering; Treatment Outcome | 2020 |
Concepts and Controversies: Lipid Management in Patients with Chronic Kidney Disease.
Topics: Atherosclerosis; Ezetimibe; Fibric Acids; Glomerular Filtration Rate; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Lipids; Niacin; Patient Acuity; PCSK9 Inhibitors; Practice Guidelines as Topic; Proprotein Convertase 9; Randomized Controlled Trials as Topic; Renal Dialysis; Renal Insufficiency, Chronic; Risk Factors | 2021 |
New possible pharmacological targets for statins and ezetimibe.
Topics: Animals; Atherosclerosis; Diabetic Angiopathies; Dyslipidemias; Endothelial Cells; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Muscle, Smooth, Vascular; Myocytes, Smooth Muscle; Signal Transduction | 2020 |
Efficacy of Statin/Ezetimibe for Secondary Prevention of Atherosclerotic Cardiovascular Disease in Asian Populations: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Topics: Anticholesteremic Agents; Asian People; Atherosclerosis; Biomarkers; C-Reactive Protein; Drug Therapy, Combination; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Randomized Controlled Trials as Topic; Secondary Prevention | 2020 |
LDL-cholesterol reduction in chronic kidney disease: options beyond statins.
Topics: Antibodies, Monoclonal; Atherosclerosis; Cholesterol, LDL; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; PCSK9 Inhibitors; Renal Insufficiency, Chronic | 2020 |
The Role of Statins in Current Guidelines.
Topics: Atherosclerosis; Cholesterol, LDL; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; PCSK9 Inhibitors; Practice Guidelines as Topic; Primary Prevention; Randomized Controlled Trials as Topic; Risk Factors; Serine Proteinase Inhibitors | 2020 |
Bempedoic Acid: A New Tool in the Battle Against Hyperlipidemia.
Topics: Atherosclerosis; Dicarboxylic Acids; Drug Therapy, Combination; Ezetimibe; Fatty Acids; Humans; Hyperlipidemias; Hyperlipoproteinemia Type II; Hypolipidemic Agents | 2021 |
Lipid-Lowering Therapies for Atherosclerosis: Statins, Fibrates, Ezetimibe and PCSK9 Monoclonal Antibodies.
Topics: Antibodies, Monoclonal; Atherosclerosis; Cholesterol, LDL; Ezetimibe; Fibric Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Myocardial Infarction; Proprotein Convertase 9 | 2021 |
Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel.
Topics: Anticholesteremic Agents; Atherosclerosis; Cholesterol, HDL; Cholesterol, LDL; Consensus; Epidemiologic Methods; Ezetimibe; Genetic Predisposition to Disease; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Lipoproteins, LDL; PCSK9 Inhibitors | 2017 |
Incorporation of PCSK9 inhibitors into prevention of atherosclerotic cardiovascular disease.
Topics: Anticholesteremic Agents; Atherosclerosis; Cardiovascular Diseases; Cholesterol, LDL; Drug Therapy, Combination; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; PCSK9 Inhibitors; Practice Guidelines as Topic; Proprotein Convertase 9 | 2017 |
Molecular aspects of hypercholesterolemia treatment: current perspectives and hopes.
Topics: Angiopoietin-Like Protein 3; Angiopoietin-like Proteins; Anticholesteremic Agents; Atherosclerosis; Bile Acids and Salts; Cholesterol, LDL; Disease Progression; Ezetimibe; Genetic Therapy; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Intestinal Absorption; Intestinal Mucosa; MicroRNAs; Mutation; PCSK9 Inhibitors; Proprotein Convertase 9; Receptors, LDL; RNA, Small Interfering; Sequestering Agents | 2018 |
Efficacy and safety of alirocumab among individuals with diabetes mellitus and atherosclerotic cardiovascular disease in the ODYSSEY phase 3 trials.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Atherosclerosis; Cardiovascular Diseases; Clinical Trials, Phase III as Topic; Diabetes Mellitus; Diabetic Angiopathies; Ezetimibe; Female; Humans; Male; Middle Aged; Randomized Controlled Trials as Topic; Treatment Outcome | 2018 |
Recent Updates on the Use of PCSK9 Inhibitors in Patients with Atherosclerotic Cardiovascular Disease.
Topics: Aged; Antibodies, Monoclonal, Humanized; Anticholesteremic Agents; Atherosclerosis; Cholesterol, LDL; Drug Therapy, Combination; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; PCSK9 Inhibitors; Primary Prevention; Risk Factors; Secondary Prevention | 2019 |
Evaluating the efficacy and safety of atorvastatin + ezetimibe in a fixed-dose combination for the treatment of hypercholesterolemia.
Topics: Anticholesteremic Agents; Atherosclerosis; Atorvastatin; Cardiovascular Diseases; Drug Combinations; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lipids; Risk Factors; Simvastatin | 2019 |
The 2018 Cholesterol Management Guidelines: Topics in Secondary ASCVD Prevention Clinicians Need to Know.
Topics: Aged; Antibodies, Monoclonal, Humanized; Anticholesteremic Agents; Atherosclerosis; Cholesterol, LDL; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; PCSK9 Inhibitors; Secondary Prevention | 2019 |
Serum lipids and prevention of atherosclerotic cardiovascular events in hemodialysis patients.
Topics: Asian People; Atherosclerosis; Azetidines; Cardiovascular Diseases; Cholesterol; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Lipids; Practice Guidelines as Topic; Renal Dialysis; Renal Insufficiency, Chronic | 2014 |
Non-cholesterol sterols and cholesterol metabolism in sitosterolemia.
Topics: Absorption; Atherosclerosis; ATP Binding Cassette Transporter, Subfamily G; ATP-Binding Cassette Transporters; Azetidines; Cholesterol; Disease Progression; Ezetimibe; Humans; Hypercholesterolemia; Intestinal Diseases; Kinetics; Lipid Metabolism, Inborn Errors; Membrane Proteins; Membrane Transport Proteins; Phytosterols; Sitosterols; Sterol O-Acyltransferase; Sterol O-Acyltransferase 2; Sterols; Xanthomatosis | 2013 |
Sitosterolemia: diagnosis, investigation, and management.
Topics: Anemia, Hemolytic; Animals; Anticholesteremic Agents; Atherosclerosis; Azetidines; Ezetimibe; Humans; Hypercholesterolemia; Intestinal Diseases; Lipid Metabolism, Inborn Errors; Mice; Phytosterols; Thrombocytopenia; Xanthomatosis | 2014 |
PCSK9 and its modulation.
Topics: Age Factors; Atherosclerosis; Azetidines; Cholesterol; Circadian Rhythm; Diet; Drugs, Chinese Herbal; Exercise; Ezetimibe; Fibric Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Insulin Resistance; Kidney Diseases; Liver Regeneration; Molecular Targeted Therapy; Proprotein Convertase 9; Proprotein Convertases; Risk Factors; Serine Endopeptidases | 2015 |
Effect of statin therapy on plasma proprotein convertase subtilisin kexin 9 (PCSK9) concentrations: a systematic review and meta-analysis of clinical trials.
Topics: Adult; Anticholesteremic Agents; Atherosclerosis; Cholesterol, LDL; Clinical Trials as Topic; Coronary Artery Disease; Drug Therapy, Combination; Dyslipidemias; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Likelihood Functions; Male; Middle Aged; Proprotein Convertase 9; Proprotein Convertases; Regression Analysis; Serine Endopeptidases; Time Factors | 2015 |
Cardiovascular Risk Reduction in Patients with Nonalcoholic Fatty Liver Disease: The Potential Role of Ezetimibe.
Topics: Anticholesteremic Agents; Atherosclerosis; Cardiovascular Diseases; Dyslipidemias; Endothelium, Vascular; Ezetimibe; Humans; Inflammation; Insulin Resistance; Intra-Abdominal Fat; Liver; Metabolic Syndrome; Non-alcoholic Fatty Liver Disease; Obesity; Obesity, Abdominal; Risk Reduction Behavior; Thrombophilia | 2016 |
Effect of ezetimibe on plasma adipokines: a systematic review and meta-analysis.
Topics: Adiponectin; Anticholesteremic Agents; Atherosclerosis; Drug Therapy, Combination; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Interleukin-6; Leptin; Plasminogen Activator Inhibitor 1; Randomized Controlled Trials as Topic; Tumor Necrosis Factor-alpha | 2017 |
Hypercholesterolemia As a Risk Factor for Cardiovascular Disease: Current Controversial Therapeutic Management.
Topics: Animals; Anticholesteremic Agents; Atherosclerosis; Biological Transport; Cardiovascular Diseases; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Receptors, LDL; Risk Factors | 2016 |
[Crosstalk between cholesterol homeostasis and drug metabolism].
Topics: Animals; Anticholesteremic Agents; Atherosclerosis; Azetidines; Bile; Cardiovascular Diseases; Cholesterol; Cholesterol, Dietary; Cytochrome P-450 Enzyme System; Ezetimibe; Feedback, Physiological; Homeostasis; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Liver; Pharmaceutical Preparations; Receptor Cross-Talk; Receptors, Cytoplasmic and Nuclear | 2008 |
Cholesterol homeostasis by the intestine: lessons from Niemann-Pick C1 Like 1 [NPC1L1).
Topics: Animals; Anticholesteremic Agents; Atherosclerosis; Azetidines; Cholesterol; Cholesterol, Dietary; Disease Progression; Ezetimibe; Humans; Intestinal Absorption; Intestinal Mucosa | 2008 |
Role of ezetimibe in the management of patients with atherosclerosis.
Topics: Anticholesteremic Agents; Atherosclerosis; Azetidines; Cardiovascular Diseases; Cholesterol, LDL; Down-Regulation; Evidence-Based Medicine; Ezetimibe; Humans; Practice Guidelines as Topic; Time Factors; Treatment Outcome | 2009 |
The use of lipid-lowering drug therapy in children and adolescents.
Topics: Adolescent; Atherosclerosis; Azetidines; Bile Acids and Salts; Cardiovascular Diseases; Child; Cholesterol; Clofibric Acid; Disease Progression; Dyslipidemias; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Ion Exchange Resins; Niacin; Practice Guidelines as Topic; Treatment Outcome | 2009 |
Impact of ezetimibe on atherosclerosis: is the jury still out?
Topics: Anticholesteremic Agents; Atherosclerosis; Azetidines; Cardiovascular Diseases; Ezetimibe; Humans; Risk Factors | 2009 |
Pleiotropic effects of ezetimibe: do they really exist?
Topics: Animals; Anticholesteremic Agents; Atherosclerosis; Azetidines; Biomarkers; Disease Models, Animal; Endothelium, Vascular; Ezetimibe; Humans; Inflammation; Inflammation Mediators; Lipid Metabolism; Platelet Aggregation; Treatment Outcome | 2010 |
Model of intestinal chylomicron over-production and ezetimibe treatment: impact on the retention of cholesterol in arterial vessels.
Topics: Animals; Anticholesteremic Agents; Arteries; Atherosclerosis; Azetidines; Biological Transport; Cholesterol; Chylomicrons; Disease Models, Animal; Drug Therapy, Combination; Dyslipidemias; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Insulin Resistance; Intestinal Absorption; Intestinal Mucosa; Intestines; Metabolic Syndrome; Rats | 2010 |
Niemann-pick C1-like 1 (NPC1L1) protein in intestinal and hepatic cholesterol transport.
Topics: Animals; Anticholesteremic Agents; Atherosclerosis; Azetidines; Biliary Tract; Biological Transport; Carrier Proteins; Cholesterol; Endocytosis; Ezetimibe; Fatty Liver; Humans; Intestinal Absorption; Intestinal Mucosa; Intestines; Liver; Membrane Proteins; Membrane Transport Proteins; Mice; Obesity; Phytosterols; Primates | 2011 |
Reversible and non-reversible cardiovascular risk in patients treated with lipid-lowering therapy: analysis of SEAS and JUPITER trials.
Topics: Anticholesteremic Agents; Atherosclerosis; Azetidines; Clinical Trials as Topic; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Risk Factors | 2010 |
Potential therapeutic uses for ezetimibe beyond lowering LDL-c to decrease cardiovascular events.
Topics: Anticholesteremic Agents; Atherosclerosis; Azetidines; Cholesterol, LDL; Clinical Trials as Topic; Ezetimibe; Fatty Liver; Female; Gallstones; Humans; Intestinal Absorption; Male | 2010 |
Ezetimibe and vascular inflammation.
Topics: Animals; Anticholesteremic Agents; Arteritis; Atherosclerosis; Azetidines; Cholesterol, LDL; Ezetimibe; Humans; Hypercholesterolemia; Meta-Analysis as Topic | 2011 |
Ezetimibe and reactive oxygen species.
Topics: Animals; Atherosclerosis; Azetidines; Cholesterol, LDL; Ezetimibe; Humans; Hypercholesterolemia; Oxidative Stress; Reactive Oxygen Species | 2011 |
New concept of vascular calcification and metabolism.
Topics: Animals; Atherosclerosis; Azetidines; Calcinosis; Ezetimibe; Humans; Lipid Metabolism | 2011 |
Ezetimibe; more than a low density lipoprotein cholesterol lowering drug? An update after 4 years.
Topics: Anticholesteremic Agents; Atherosclerosis; Azetidines; Cholesterol, LDL; Ezetimibe; Humans; Treatment Outcome | 2011 |
Therapies targeting exogenous cholesterol uptake: new insights and controversies.
Topics: Animals; Anticholesteremic Agents; Atherosclerosis; ATP-Binding Cassette Transporters; Azetidines; Bile Acids and Salts; Biological Transport; Cholesterol; Cholesterol, HDL; Drug Discovery; Ezetimibe; Humans; Intestinal Absorption; Metabolic Diseases; Mice; Molecular Targeted Therapy; Sitosterols; Sterol O-Acyltransferase; Sterol O-Acyltransferase 2 | 2011 |
Effects of ezetimibe on atherosclerosis in preclinical models.
Topics: Animals; Anticholesteremic Agents; Apolipoproteins B; Apolipoproteins E; Atherosclerosis; Azetidines; Cardiovascular Diseases; Cholesterol, LDL; Disease Models, Animal; Drug Evaluation, Preclinical; Ezetimibe; Mice; Mice, Knockout; Rabbits; Risk; Simvastatin | 2011 |
Where does the interplay between cholesterol absorption and synthesis in the context of statin and/or ezetimibe treatment stand today?
Topics: Anticholesteremic Agents; Atherosclerosis; Azetidines; Cholesterol; Evidence-Based Medicine; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Intestinal Absorption; Intestinal Mucosa; Intestines; Liver; Treatment Outcome | 2011 |
Lipid-lowering therapy in chronic kidney disease: is there a role for ezetimibe?
Topics: Anticholesteremic Agents; Atherosclerosis; Azetidines; Drug Therapy, Combination; Ezetimibe; Humans; Renal Dialysis; Renal Insufficiency, Chronic; Simvastatin | 2012 |
Inhibition of cholesterol absorption: targeting the intestine.
Topics: Animals; Anticholesteremic Agents; Apolipoproteins B; Atherosclerosis; Azetidines; Bile Acids and Salts; Cholesterol; Ezetimibe; Heart Diseases; Humans; Intestinal Absorption; Liver X Receptors; Molecular Targeted Therapy; Orphan Nuclear Receptors; Phytosterols; Sterol O-Acyltransferase; Transcription, Genetic | 2012 |
Lipid abnormalities in patients with chronic kidney disease: implications for the pathophysiology of atherosclerosis.
Topics: Animals; Apolipoproteins B; Atherosclerosis; Azetidines; Cardiovascular Diseases; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney Failure, Chronic; Lipids; Lipoprotein(a); Liver; Triglycerides | 2013 |
Plant sterols and atherosclerosis.
Topics: Alleles; Animals; Anticholesteremic Agents; Atherosclerosis; ATP Binding Cassette Transporter, Subfamily G, Member 5; ATP Binding Cassette Transporter, Subfamily G, Member 8; ATP-Binding Cassette Transporters; Azetidines; Cholesterol, LDL; Ezetimibe; Genetic Loci; Humans; Lipoproteins; Phytosterols; Phytotherapy; Randomized Controlled Trials as Topic; Risk Factors; Sitosterols | 2013 |
Cholesterol absorption inhibitors as a therapeutic option for hypercholesterolaemia.
Topics: Acetyl-CoA C-Acyltransferase; Animals; Anticholesteremic Agents; Atherosclerosis; Azetidines; Bile Acids and Salts; Carrier Proteins; Cholesterol, Dietary; Drugs, Investigational; Ezetimibe; Humans; Hypercholesterolemia; Intestinal Absorption; Phytosterols | 2006 |
[Influence of combined, hypolipemic therapy on lipids and non-lipid atherosclerosis risk factors].
Topics: Anticholesteremic Agents; Atherosclerosis; Azetidines; Cholesterol, HDL; Cholesterol, LDL; Clofibric Acid; Drug Therapy, Combination; Ezetimibe; Humans; Hyperlipidemias; Hypolipidemic Agents; Lipids; Niacin; Risk Factors; Simvastatin | 2007 |
[Dual inhibition of cholesterol using the drug combination ezetimibe/simvastatin?].
Topics: Anticholesteremic Agents; Atherosclerosis; Azetidines; Cholesterol, LDL; Drug Combinations; Drug Therapy, Combination; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Simvastatin | 2007 |
Ezetimibe plus simvastatin cardiovascular outcomes study program.
Topics: Acute Coronary Syndrome; Anticholesteremic Agents; Aortic Valve Stenosis; Atherosclerosis; Azetidines; Disease Progression; Drug Therapy, Combination; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Kidney Failure, Chronic; Simvastatin; Treatment Outcome | 2008 |
32 trial(s) available for ezetimibe and Atherogenesis
| Article | Year |
|---|---|
Main differences between two highly effective lipid-lowering therapies in subclasses of lipoproteins in patients with acute myocardial infarction.
Topics: Aged; Atherosclerosis; Cholesterol; Cholesterol, LDL; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lipids; Lipoproteins; Liver; Male; Middle Aged; Rosuvastatin Calcium; Simvastatin; ST Elevation Myocardial Infarction | 2021 |
Long-term efficacy and safety of moderate-intensity statin with ezetimibe combination therapy versus high-intensity statin monotherapy in patients with atherosclerotic cardiovascular disease (RACING): a randomised, open-label, non-inferiority trial.
Topics: Anticholesteremic Agents; Atherosclerosis; Cardiovascular Diseases; Cholesterol, LDL; Drug Therapy, Combination; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Rosuvastatin Calcium; Treatment Outcome | 2022 |
Potential Cardiovascular Events Avoided with Bempedoic Acid Plus Ezetimibe Fixed-Dose Combination Compared with Ezetimibe Alone in Patients with Atherosclerotic Cardiovascular Disease Taking Maximally Tolerated Statins.
Topics: Anticholesteremic Agents; Atherosclerosis; Azetidines; Cardiovascular Diseases; Cholesterol, LDL; Drug Therapy, Combination; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Quality of Life; Treatment Outcome | 2023 |
Small Interfering RNA to Reduce Lipoprotein(a) in Cardiovascular Disease.
Topics: Anticholesteremic Agents; Atherosclerosis; Cardiovascular Diseases; Double-Blind Method; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lipoprotein(a); Liver; PCSK9 Inhibitors; RNA, Small Interfering | 2022 |
Moderate-intensity statin with ezetimibe vs. high-intensity statin in patients with diabetes and atherosclerotic cardiovascular disease in the RACING trial.
Topics: Anticholesteremic Agents; Atherosclerosis; Cardiovascular Diseases; Cholesterol, LDL; Diabetes Mellitus; Drug Therapy, Combination; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Treatment Outcome | 2023 |
Effect of rosuvastatin 20 mg versus rosuvastatin 5 mg plus ezetimibe on statin side-effects in elderly patients with atherosclerotic cardiovascular disease: Rationale and design of a randomized, controlled SaveSAMS trial.
Topics: Aged; Anticholesteremic Agents; Atherosclerosis; Cardiovascular Diseases; Cholesterol, LDL; Drug Therapy, Combination; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Rosuvastatin Calcium; Treatment Outcome | 2023 |
Combination Moderate-Intensity Statin and Ezetimibe Therapy for Elderly Patients With Atherosclerosis.
Topics: Aged; Anticholesteremic Agents; Atherosclerosis; Cardiovascular Diseases; Drug Therapy, Combination; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Treatment Outcome | 2023 |
Moderate-Intensity Statin With Ezetimibe Combination Therapy vs High-Intensity Statin Monotherapy in Patients at Very High Risk of Atherosclerotic Cardiovascular Disease: A Post Hoc Analysis From the RACING Randomized Clinical Trial.
Topics: Anticholesteremic Agents; Atherosclerosis; Cardiovascular Diseases; Cholesterol, LDL; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Rosuvastatin Calcium; United States | 2023 |
The Efficacy and Safety of Moderate-Intensity Rosuvastatin with Ezetimibe versus High-Intensity Rosuvastatin in High Atherosclerotic Cardiovascular Disease Risk Patients with Type 2 Diabetes Mellitus: A Randomized, Multicenter, Open, Parallel, Phase 4 Stu
Topics: Anticholesteremic Agents; Atherosclerosis; Cardiovascular Diseases; Cholesterol, LDL; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Ezetimibe; Humans; Hypercholesterolemia; Rosuvastatin Calcium | 2023 |
Ezetimibe Lipid-Lowering Trial on Prevention of Atherosclerotic Cardiovascular Disease in 75 or Older (EWTOPIA 75): A Randomized, Controlled Trial.
Topics: Aged; Aged, 80 and over; Atherosclerosis; Ezetimibe; Female; Follow-Up Studies; Humans; Hypolipidemic Agents; Incidence; Japan; Male; Primary Prevention; Prospective Studies; Survival Analysis; Treatment Outcome | 2019 |
A Comparison of Two LDL Cholesterol Targets after Ischemic Stroke.
Topics: Adult; Aged; Anticholesteremic Agents; Atherosclerosis; Brain Ischemia; Cardiovascular Diseases; Cholesterol, LDL; Drug Therapy, Combination; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Intention to Treat Analysis; Ischemic Attack, Transient; Kaplan-Meier Estimate; Male; Middle Aged; Stroke | 2020 |
Low-density lipoprotein cholesterol treatment and outcomes in patients with type 2 diabetes and established cardiovascular disease: Insights from TECOS.
Topics: Aged; Atherosclerosis; Cardiovascular Diseases; Cholesterol, LDL; Diabetes Mellitus, Type 2; Double-Blind Method; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemic Agents; Male; Middle Aged; Myocardial Infarction; Reference Values; Sitagliptin Phosphate; Stroke | 2020 |
Comparative effects of cholesteryl ester transfer protein inhibition, statin or ezetimibe on lipid factors: The ACCENTUATE trial.
Topics: Aged; Anticholesteremic Agents; Atherosclerosis; Atorvastatin; Benzodiazepines; Biomarkers; Cholesterol Ester Transfer Proteins; Double-Blind Method; Drug Therapy, Combination; Dyslipidemias; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation Mediators; Lipids; Male; Middle Aged; Time Factors; Treatment Outcome; United States | 2017 |
Effect of Combination Therapy of Ezetimibe and Atorvastatin on Remnant Lipoprotein Versus Double Atorvastatin Dose in Egyptian Diabetic Patients.
Topics: Anticholesteremic Agents; Apolipoproteins B; Atherosclerosis; Atorvastatin; Cholesterol; Cholesterol, LDL; Diabetes Mellitus; Drug Therapy, Combination; Egypt; Ezetimibe; Female; Gastric Stump; Humans; Lipoproteins; Male; Middle Aged; Prospective Studies; Triglycerides | 2018 |
Efficacy, safety and effect on biomarkers related to cholesterol and lipoprotein metabolism of rosuvastatin 10 or 20 mg plus ezetimibe 10 mg vs. simvastatin 40 or 80 mg plus ezetimibe 10 mg in high-risk patients: Results of the GRAVITY randomized study.
Topics: Absorption; Adult; Atherosclerosis; Azetidines; Biomarkers; Cholesterol, LDL; Coronary Disease; Drug Administration Schedule; Ezetimibe; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lipids; Lipoproteins; Male; Pyrimidines; Risk; Rosuvastatin Calcium; Simvastatin; Sitosterols; Sulfonamides; Treatment Outcome | 2014 |
Atorvastatin 10 mg plus ezetimibe versus titration to atorvastatin 40 mg: attainment of European and Canadian guideline lipid targets in high-risk subjects ≥65 years.
Topics: Aged; Anticholesteremic Agents; Atherosclerosis; Atorvastatin; Azetidines; Canada; Cholesterol, LDL; Double-Blind Method; Europe; Ezetimibe; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Practice Guidelines as Topic; Pyrroles; Randomized Controlled Trials as Topic; Retrospective Studies; Risk Factors; Treatment Outcome | 2014 |
Renal and vascular protective effects of ezetimibe in chronic kidney disease.
Topics: Aged; Ankle Brachial Index; Anticholesteremic Agents; Atherosclerosis; Azetidines; Cardiovascular Diseases; Carotid Intima-Media Thickness; Cholesterol, LDL; Dyslipidemias; Ezetimibe; Female; Glomerular Filtration Rate; Humans; Male; Middle Aged; Renal Insufficiency, Chronic; Risk Factors | 2014 |
Impact of the ENHANCE trial on the use of ezetimibe in the United States and Canada.
Topics: Anticholesteremic Agents; Atherosclerosis; Azetidines; Canada; Cholesterol; Disease Progression; Dose-Response Relationship, Drug; Drug Costs; Drug Prescriptions; Ezetimibe; Follow-Up Studies; Humans; Hypercholesterolemia; Prevalence; Retrospective Studies; Time Factors; Treatment Outcome; United States | 2014 |
LDL-migration index (LDL-MI), an indicator of small dense low-density lipoprotein (sdLDL), is higher in non-alcoholic steatohepatitis than in non-alcoholic fatty liver: a multicenter cross-sectional study.
Topics: Adult; Anticholesteremic Agents; Atherosclerosis; Atorvastatin; Azetidines; Cross-Sectional Studies; Ezetimibe; Female; Heptanoic Acids; Humans; Lipoproteins, LDL; Male; Middle Aged; Non-alcoholic Fatty Liver Disease; Pyrroles; Risk Factors | 2014 |
Ezetimibe ameliorates atherogenic lipids profiles, insulin resistance and hepatocyte growth factor in obese patients with hypercholesterolemia.
Topics: Atherosclerosis; Biomarkers; Drug Therapy, Combination; Ezetimibe; Female; Hepatocyte Growth Factor; Humans; Hypercholesterolemia; Insulin Resistance; Lipids; Male; Middle Aged; Obesity | 2015 |
[Effect of pravastatine plus ezetimibe on carotid intima media thickness in patients with lupus erythematosus].
Topics: Adult; Anticholesteremic Agents; Atherosclerosis; Carotid Intima-Media Thickness; Drug Administration Schedule; Drug Therapy, Combination; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Longitudinal Studies; Lupus Erythematosus, Systemic; Middle Aged; Pravastatin; Prospective Studies; Treatment Outcome | 2015 |
Detrimental effects of high-fat diet loading on vascular endothelial function and therapeutic efficacy of ezetimibe and statins in patients with type 2 diabetes.
Topics: Adult; Aged; Atherosclerosis; Cross-Sectional Studies; Diabetes Mellitus, Type 2; Diet, High-Fat; Dietary Fats; Endothelium, Vascular; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperemia; Hyperlipidemias; Male; Middle Aged; Pilot Projects; Postprandial Period; Treatment Outcome | 2016 |
Flow-mediated dilation in patients with coronary artery disease is enhanced by high dose atorvastatin compared to combined low dose atorvastatin and ezetimibe: results of the CEZAR study.
Topics: Aged; Anticholesteremic Agents; Atherosclerosis; Atorvastatin; Azetidines; C-Reactive Protein; Cholesterol; Cholesterol, LDL; Coronary Artery Disease; Double-Blind Method; Ezetimibe; Female; Heptanoic Acids; Humans; Male; Middle Aged; Pyrroles; Treatment Outcome | 2009 |
The ARBITER 6-HALTS Trial (Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol 6-HDL and LDL Treatment Strategies in Atherosclerosis): final results and the impact of medication adherence, dose, and treatment duration.
Topics: Aged; Anticholesteremic Agents; Atherosclerosis; Azetidines; Carotid Artery, Common; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Dose-Response Relationship, Drug; Ezetimibe; Female; Follow-Up Studies; Humans; Male; Medication Adherence; Niacin; Single-Blind Method; Time Factors; Treatment Outcome; Tunica Intima; Ultrasonography | 2010 |
Observed and predicted reduction of ischemic cardiovascular events in the Simvastatin and Ezetimibe in Aortic Stenosis trial.
Topics: Aged; Aged, 80 and over; Anticholesteremic Agents; Aortic Valve Stenosis; Apolipoproteins B; Atherosclerosis; Azetidines; Cholesterol, HDL; Cholesterol, LDL; Disease Progression; Dose-Response Relationship, Drug; Drug Therapy, Combination; Echocardiography, Doppler; Ezetimibe; Female; Follow-Up Studies; Humans; Incidence; Male; Middle Aged; Prognosis; Simvastatin; Time Factors | 2010 |
Study of Heart and Renal Protection (SHARP): randomized trial to assess the effects of lowering low-density lipoprotein cholesterol among 9,438 patients with chronic kidney disease.
Topics: Adult; Aged; Anticholesteremic Agents; Atherosclerosis; Azetidines; Cholesterol, LDL; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Ezetimibe; Female; Follow-Up Studies; Humans; Incidence; Kidney Failure, Chronic; Male; Middle Aged; Renal Dialysis; Retrospective Studies; Simvastatin; Treatment Outcome | 2010 |
The role of niacin in raising high-density lipoprotein cholesterol to reduce cardiovascular events in patients with atherosclerotic cardiovascular disease and optimally treated low-density lipoprotein cholesterol Rationale and study design. The Atherothro
Topics: Anticholesteremic Agents; Atherosclerosis; Azetidines; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Ezetimibe; Humans; Hypolipidemic Agents; Metabolic Syndrome; Niacin; Research Design; Simvastatin; Treatment Outcome | 2011 |
The effect of ezetimibe on peripheral arterial atherosclerosis depends upon statin use at baseline.
Topics: Aged; Anticholesteremic Agents; Atherosclerosis; Azetidines; Cholesterol, LDL; Double-Blind Method; Ezetimibe; Female; Femoral Artery; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Magnetic Resonance Imaging; Male; Middle Aged; Peripheral Arterial Disease; Plaque, Atherosclerotic; Prospective Studies; Simvastatin; Treatment Outcome | 2011 |
Ezetimibe alone and in combination lowers the concentration of small, dense low-density lipoproteins in type 2 diabetes mellitus.
Topics: Aged; Analysis of Variance; Anticholesteremic Agents; Atherosclerosis; Azetidines; Biomarkers; Centrifugation, Density Gradient; Diabetes Mellitus, Type 2; Down-Regulation; Drug Combinations; Ezetimibe; Ezetimibe, Simvastatin Drug Combination; Female; Germany; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Linear Models; Lipoproteins, LDL; Male; Middle Aged; Risk Assessment; Risk Factors; Simvastatin; Time Factors; Treatment Outcome | 2012 |
Influence of ezetimibe monotherapy on ischemia-modified albumin levels in hypercholesterolemic patients.
Topics: Aged; Anticholesteremic Agents; Atherosclerosis; Azetidines; Biomarkers; Cholesterol, LDL; Ezetimibe; Female; Humans; Hypercholesterolemia; Male; Middle Aged; Oxidative Stress; Prospective Studies; Regression Analysis; Risk Factors; Serum Albumin; Serum Albumin, Human | 2011 |
Paradoxical progression of atherosclerosis related to low-density lipoprotein reduction and exposure to ezetimibe.
Topics: Aged; Anticholesteremic Agents; Atherosclerosis; Azetidines; Carotid Artery Diseases; Carotid Artery, Common; Carotid Intima-Media Thickness; Cholesterol, LDL; Coronary Artery Disease; Coronary Disease; Disease Progression; Ezetimibe; Female; Humans; Male; Risk Factors | 2012 |
Lipid-altering efficacy of switching from atorvastatin 10 mg/day to ezetimibe/simvastatin 10/20 mg/day compared to doubling the dose of atorvastatin in hypercholesterolaemic patients with atherosclerosis or coronary heart disease.
Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Apolipoproteins B; Atherosclerosis; Atorvastatin; Azetidines; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Double-Blind Method; Drug Therapy, Combination; Europe; Ezetimibe; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Pyrroles; Simvastatin; Taiwan; Treatment Outcome | 2005 |
107 other study(ies) available for ezetimibe and Atherogenesis
| Article | Year |
|---|---|
A comparison of the effects of monotherapy with rosuvastatin, atorvastatin or ezetimibe versus combination treatment with rosuvastatin-ezetimibe and atorvastatin-ezetimibe on the integrity of vascular endothelial cells damaged by oxidized cholesterol.
Topics: Atherosclerosis; Atorvastatin; Cholesterol; Cholesterol, LDL; Drug Therapy, Combination; Dyslipidemias; Ezetimibe; Gene Expression Regulation; Human Umbilical Vein Endothelial Cells; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Intercellular Adhesion Molecule-1; Occludin; Risk Factors; Rosuvastatin Calcium; Zonula Occludens-1 Protein | 2021 |
The Projected Impact of Population-Wide Achievement of LDL Cholesterol <70 mg/dL on the Number of Recurrent Events Among US Adults with ASCVD.
Topics: Adult; Anticholesteremic Agents; Atherosclerosis; Cardiovascular Diseases; Cholesterol, LDL; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Nutrition Surveys; United States | 2023 |
Lipid lowering therapy in primary and secondary prevention in Austria: are LDL-C goals achieved? : Results from the DA VINCI study.
Topics: Anticholesteremic Agents; Atherosclerosis; Austria; Cardiovascular Diseases; Cholesterol, LDL; Cross-Sectional Studies; Ezetimibe; Goals; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Proprotein Convertase 9; Secondary Prevention; Treatment Outcome | 2022 |
Comparison of Evolocumab and Ezetimibe, Both Combined with Statin Therapy, for Patients with Recent Acute Coronary Syndrome: A Cost-Effectiveness Analysis from the Chinese Healthcare Perspective.
Topics: Acute Coronary Syndrome; Anticholesteremic Agents; Atherosclerosis; Cardiovascular Diseases; Cholesterol, LDL; Cost-Benefit Analysis; Cost-Effectiveness Analysis; Ezetimibe; Homozygous Familial Hypercholesterolemia; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Proprotein Convertase 9 | 2023 |
Combination of ezetimibe and moderate-intensity statin for patients with atherosclerotic cardiovascular disease: a paradigm shift in lipid management landscape.
Topics: Anticholesteremic Agents; Atherosclerosis; Cardiovascular Diseases; Drug Therapy, Combination; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Treatment Outcome | 2022 |
Use of lipid-lowering therapies in patients with chronic kidney disease and atherosclerotic cardiovascular disease: 2-year results from Getting to an imprOved Understanding of Low-Density lipoprotein cholesterol and dyslipidemia management (GOULD).
Topics: Anticholesteremic Agents; Atherosclerosis; Cardiovascular Diseases; Cholesterol; Cholesterol, LDL; Dyslipidemias; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Renal Insufficiency, Chronic | 2022 |
Lipid-Lowering Therapy Use and Intensification Among United States Veterans Following Myocardial Infarction or Coronary Revascularization Between 2015 and 2019.
Topics: Aged; Anticholesteremic Agents; Atherosclerosis; Cholesterol, LDL; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Myocardial Infarction; United States; Veterans | 2022 |
Simulation study on LDL cholesterol target attainment, treatment costs, and ASCVD events with bempedoic acid in patients at high and very-high cardiovascular risk.
Topics: Anticholesteremic Agents; Atherosclerosis; Cardiovascular Diseases; Cholesterol, LDL; Ezetimibe; Health Care Costs; Heart Disease Risk Factors; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; PCSK9 Inhibitors; Risk Factors | 2022 |
Establishment of a lipid metabolism disorder model in ApoEb mutant zebrafish.
Topics: Animals; Apolipoproteins E; Atherosclerosis; Ezetimibe; Hypercholesterolemia; Hyperlipidemias; Lipid Metabolism; Mammals; Simvastatin; Zebrafish | 2022 |
In ASCVD, moderate-intensity statin + ezetimibe was noninferior to high-intensity statin alone at 3 y.
Topics: Anticholesteremic Agents; Atherosclerosis; Drug Therapy, Combination; Equivalence Trials as Topic; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Randomized Controlled Trials as Topic; Treatment Outcome | 2022 |
Trends in Lipid-Lowering Prescriptions: Increasing Use of Guideline-Concordant Pharmacotherapies, U.S., 2017‒2022.
Topics: Adult; Atherosclerosis; Cardiovascular Diseases; Cholesterol; Cholesterol, LDL; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; PCSK9 Inhibitors; Prescriptions; Proprotein Convertase 9 | 2023 |
Lipid-lowering treatment among older patients with atherosclerotic cardiovascular disease.
Topics: Aged; Atherosclerosis; Cardiovascular Diseases; Cholesterol, LDL; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; PCSK9 Inhibitors; Proprotein Convertase 9; Retrospective Studies | 2023 |
RACING to judgement: weighing the value of pre-specified subgroup analyses.
Topics: Atherosclerosis; Cardiovascular Diseases; Diabetes Mellitus; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Judgment | 2023 |
The effect of lipid-lowering therapies on the pro-inflammatory and anti-inflammatory properties of vascular endothelial cells.
Topics: Anti-Inflammatory Agents; Anticholesteremic Agents; Atherosclerosis; Atorvastatin; Drug Therapy, Combination; Endothelial Cells; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Interleukin-10; Interleukin-18; Interleukin-23; RNA, Messenger; Rosuvastatin Calcium; Transforming Growth Factor beta | 2023 |
Achievement Rates for Low-Density Lipoprotein Cholesterol Goals in Patients at High Risk of Atherosclerotic Cardiovascular Disease in a Real-World Setting in Japan.
Topics: Anticholesteremic Agents; Atherosclerosis; Cardiovascular Diseases; Cholesterol, LDL; Ezetimibe; Goals; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Japan; Treatment Outcome | 2023 |
An estimation of the consequences of reinforcing the 2016 and 2019 European Society of Cardiology/European Atherosclerosis Society guidelines on current lipid-lowering treatment in patients with type 2 diabetes in tertiary care-a SwissDiab study.
Topics: Anticholesteremic Agents; Atherosclerosis; Cardiology; Cholesterol, LDL; Diabetes Mellitus, Type 2; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Tertiary Healthcare | 2023 |
Trends and outcome of statin therapy in dialysis patients with atherosclerotic cardiovascular diseases: A population-based cohort study.
Topics: Adult; Atherosclerosis; Cardiovascular Diseases; Cohort Studies; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Renal Dialysis; Retrospective Studies | 2023 |
[Hypercholesterolemia and cardiovascular risk].
Topics: Anticholesteremic Agents; Atherosclerosis; Cardiovascular Diseases; Cholesterol, LDL; Ezetimibe; Heart Disease Risk Factors; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hyperlipidemias; Proprotein Convertase 9; Risk Factors | 2023 |
Low-density lipoprotein cholesterol and non-high-density lipoprotein cholesterol in type 1 diabetes and type 2 diabetes: Lipid goal attainment in a large German-Austrian diabetes registry.
Topics: Adult; Aged; Anticholesteremic Agents; Atherosclerosis; Austria; Cholesterol; Cholesterol, LDL; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Dyslipidemias; Ezetimibe; Fibric Acids; Goals; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Proprotein Convertase 9; Registries | 2023 |
Variability in Plasma Lipids Between Intensive Statin Therapy and Conventional-Dose Statins Combined with Ezetimibe Therapy in Patients with Coronary Atherosclerosis Disease.
Topics: Aged; Anticholesteremic Agents; Atherosclerosis; Cholesterol; Coronary Artery Disease; Drug Therapy, Combination; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Retrospective Studies | 2023 |
Effect of moderate-intensity statin with ezetimibe combination vs. high-intensity statin therapy according to sex in patients with atherosclerosis.
Topics: Anticholesteremic Agents; Atherosclerosis; Cholesterol, LDL; Drug Therapy, Combination; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Rosuvastatin Calcium; Treatment Outcome | 2023 |
Proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors.
Topics: Antibodies, Monoclonal, Humanized; Anticholesteremic Agents; Atherosclerosis; Cardiovascular Diseases; Cholesterol, LDL; Drug Therapy, Combination; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; PCSK9 Inhibitors | 2019 |
Gender Disparities in Health Resource Utilization in Patients with Atherosclerotic Cardiovascular Disease: A Retrospective Cross-Sectional Study.
Topics: Aged; Atherosclerosis; Cardiologists; Cross-Sectional Studies; Ezetimibe; Female; Health Resources; Health Services; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Male; Medicare Part C; Middle Aged; Patient Acceptance of Health Care; PCSK9 Inhibitors; Registries; Retrospective Studies; Sex Factors; Socioeconomic Factors; Subtilisin; United States | 2019 |
Getting to an ImprOved Understanding of Low-Density Lipoprotein-Cholesterol and Dyslipidemia Management (GOULD): Methods and baseline data of a registry of high cardiovascular risk patients in the United States.
Topics: Aged; Atherosclerosis; Cholesterol, LDL; Diabetes Mellitus, Type 2; Dyslipidemias; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; PCSK9 Inhibitors; Registries; Retrospective Studies; United States | 2020 |
Heterozygous Ldlr-Deficient Hamster as a Model to Evaluate the Efficacy of PCSK9 Antibody in Hyperlipidemia and Atherosclerosis.
Topics: Animals; Antibodies, Monoclonal, Humanized; Atherosclerosis; Cholesterol, LDL; Cricetinae; Diet, High-Fat; Disease Models, Animal; Ezetimibe; Heterozygote; Humans; Hyperlipidemias; Male; PCSK9 Inhibitors; Receptors, LDL; Treatment Outcome; Triglycerides | 2019 |
Impact of Lipid Monitoring on Treatment Intensification of Cholesterol Lowering Therapies (from the Veterans Affairs Healthcare System).
Topics: Aged; Aged, 80 and over; Anticholesteremic Agents; Atherosclerosis; Cardiovascular Diseases; Cholesterol, LDL; Ezetimibe; Female; Guideline Adherence; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lipids; Male; Middle Aged; Monitoring, Physiologic; Odds Ratio; Treatment Outcome; United States; Veterans Health Services | 2020 |
Application of the 2019 ESC/EAS dyslipidaemia guidelines to nationwide data of patients with a recent myocardial infarction: a simulation study.
Topics: Adolescent; Adult; Aged; Anticholesteremic Agents; Atherosclerosis; Cardiology; Dyslipidemias; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Middle Aged; Myocardial Infarction; PCSK9 Inhibitors; Percutaneous Coronary Intervention; Young Adult | 2020 |
Letter by Weingärtner et al Regarding Article, "Ezetimibe Lipid-Lowering Trial on Prevention of Atherosclerotic Cardiovascular Disease in 75 or Older (EWTOPIA 75): A Randomized, Controlled Trial".
Topics: Anticholesteremic Agents; Atherosclerosis; Cardiovascular Diseases; Ezetimibe; Humans; Lipids | 2020 |
Response by Kuwabara et al to Letter Regarding Article, "Ezetimibe Lipid-Lowering Trial on Prevention of Atherosclerotic Cardiovascular Disease in 75 or Older (EWTOPIA 75): A Randomized Controlled Trial".
Topics: Anticholesteremic Agents; Atherosclerosis; Cardiovascular Diseases; Ezetimibe; Humans; Lipids | 2020 |
A practical approach to the cholesterol guidelines and ASCVD prevention.
Topics: Age Factors; Antibodies, Monoclonal, Humanized; Anticholesteremic Agents; Atherosclerosis; Autoimmune Diseases; Cholesterol, HDL; Cholesterol, LDL; Coronary Artery Disease; Diabetes Mellitus; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; PCSK9 Inhibitors; Practice Guidelines as Topic; Primary Prevention; Risk Assessment; Risk Reduction Behavior; Secondary Prevention; Vascular Calcification | 2020 |
Zebrafish atherosclerosis: Experimental definitions and difficulties.
Topics: Animals; Apolipoprotein A-II; Atherosclerosis; Cholesterol; Diet; Ezetimibe; Foam Cells; Zebrafish | 2020 |
Have We Learnt all from IMPROVE-IT? Part II. Subanalyses of the Effects of Ezetimibe Added to Statin Therapy on Selected Clinical and Laboratory Outcomes, Cost-Effectiveness, Guidelines, and Clinical Implications.
Topics: Anticholesteremic Agents; Atherosclerosis; Clinical Laboratory Techniques; Cost-Benefit Analysis; Drug Therapy, Combination; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Practice Guidelines as Topic; Treatment Outcome | 2021 |
Non-statin lipid-lowering therapy over time in very-high-risk patients: effectiveness of fixed-dose statin/ezetimibe compared to separate pill combination on LDL-C.
Topics: Aged; Anticholesteremic Agents; Atherosclerosis; Cholesterol, LDL; Cross-Sectional Studies; Drug Prescriptions; Drug Therapy, Combination; Ezetimibe; Female; General Practice; Germany; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Practice Patterns, Physicians'; Retrospective Studies; Time Factors; Treatment Outcome | 2022 |
Treatment with PCSK9 inhibitors induces a more anti-atherogenic HDL lipid profile in patients at high cardiovascular risk.
Topics: Aged; Antibodies, Monoclonal, Humanized; Anticholesteremic Agents; Atherosclerosis; Biomarkers; Cholesterol, HDL; Drug Therapy, Combination; Dyslipidemias; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Magnetic Resonance Spectroscopy; Male; Middle Aged; Particle Size; PCSK9 Inhibitors; Risk Assessment; Risk Factors; Serine Proteinase Inhibitors; Time Factors; Treatment Outcome | 2020 |
Efficient aortic lymphatic drainage is necessary for atherosclerosis regression induced by ezetimibe.
Topics: Animals; Aorta; Atherosclerosis; Ezetimibe; Lymphangiogenesis; Mice; Plaque, Atherosclerotic | 2020 |
Optimal use of lipid-lowering therapy after acute coronary syndromes: A Position Paper endorsed by the International Lipid Expert Panel (ILEP).
Topics: Acute Coronary Syndrome; Anticholesteremic Agents; Atherosclerosis; Disease Management; Ezetimibe; Humans; Lipids; PCSK9 Inhibitors | 2021 |
Effectiveness and Safety of Lipid-Lowering Drug Treatments in Japanese Patients with Familial Hypercholesterolemia: Familial Hypercholesterolemia Expert Forum (FAME) Study.
Topics: Anticholesteremic Agents; Atherosclerosis; Cholesterol; Cholesterol, LDL; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Japan; Male; Probucol; Xanthomatosis | 2022 |
Access to Nonstatin Lipid-Lowering Therapies in Patients at High Risk of Atherosclerotic Cardiovascular Disease.
Topics: Anticholesteremic Agents; Atherosclerosis; Cholesterol, LDL; Databases, Factual; Ezetimibe; Female; Humans; Hypercholesterolemia; Male; PCSK9 Inhibitors | 2017 |
Detection of atherosclerotic cardiovascular disease influences the perceived need for aggressive lipid management.
Topics: Aged; Angina, Unstable; Atherosclerosis; Cardiologists; Cardiology; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Male; Middle Aged; PCSK9 Inhibitors; Practice Patterns, Physicians'; Renal Insufficiency, Chronic; Risk Assessment; Severity of Illness Index; Surveys and Questionnaires | 2017 |
Translating Guidelines Into Practice: Interpreting the 2016 ACC Expert Consensus Decision Pathway on the Role of Non-Statin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk.
Topics: American Medical Association; Atherosclerosis; Cardiology; Cholesterol, LDL; Consensus; Drug Therapy, Combination; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Managed Care Programs; Practice Guidelines as Topic; Risk Factors; United States | 2017 |
Clinical Features and Gaps in the Management of Probable Familial Hypercholesterolemia and Cardiovascular Disease.
Topics: Adult; Aged; Anticholesteremic Agents; Atherosclerosis; Cardiovascular Diseases; Disease Management; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Male; Middle Aged; Myocardial Revascularization; Risk Factors; Treatment Outcome | 2017 |
Low-Density Lipoprotein Cholesterol and Drug Treatment to Lower Atherosclerotic Cardiovascular Disease Risk: Where Do We Stand?
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Anticholesteremic Agents; Atherosclerosis; Cholesterol, LDL; Drug Therapy, Combination; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Patient Selection; PCSK9 Inhibitors; Risk Reduction Behavior; RNA, Small Interfering | 2017 |
Low-Density Lipoprotein Cholesterol Treatment in the Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor Era: Getting Back on Target.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Anticholesteremic Agents; Atherosclerosis; Cholesterol, LDL; Drug Therapy, Combination; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Patient Care Planning; PCSK9 Inhibitors; Practice Guidelines as Topic; Primary Prevention; Risk Reduction Behavior; Secondary Prevention | 2017 |
Simulation of Lipid-Lowering Therapy Intensification in a Population With Atherosclerotic Cardiovascular Disease.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Anticholesteremic Agents; Atherosclerosis; Atorvastatin; Cholesterol, LDL; Cohort Studies; Computer Simulation; Databases, Factual; Drug Therapy, Combination; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Monte Carlo Method; Patient Care Planning; PCSK9 Inhibitors | 2017 |
Ezetimibe Use and LDL-C Goal Achievement: A Retrospective Database Analysis of Patients with Clinical Atherosclerotic Cardiovascular Disease or Probable Heterozygous Familial Hypercholesterolemia.
Topics: Aged; Aged, 80 and over; Anticholesteremic Agents; Atherosclerosis; Cholesterol, LDL; Drug Therapy, Combination; Ezetimibe; Female; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Male; Middle Aged; Retrospective Studies; Treatment Outcome | 2017 |
Treatment Patterns, Statin Intolerance, and Subsequent Cardiovascular Events Among Japanese Patients With High Cardiovascular Risk Initiating Statin Therapy.
Topics: Adult; Aged; Atherosclerosis; Cardiovascular Diseases; Cohort Studies; Comorbidity; Diabetes Mellitus, Type 2; Drug Substitution; Drug Tolerance; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Japan; Male; Middle Aged; Practice Patterns, Physicians'; Retrospective Studies | 2018 |
Lipid-Lowering Therapy With Ezetimibe Decreases Spontaneous Atherothrombotic Occlusions in a Rabbit Model of Plaque Erosion: A Role of Serum Oxysterols.
Topics: Angiotensin II; Animals; Anticholesteremic Agents; Arterial Occlusive Diseases; Atherosclerosis; Biomarkers; Cells, Cultured; Cholesterol, Dietary; Diet, High-Fat; Disease Models, Animal; Down-Regulation; Ezetimibe; Femoral Artery; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Oxysterols; Plaque, Atherosclerotic; Rabbits; Rats; Rosuvastatin Calcium; Signal Transduction; Thrombosis; Vascular System Injuries | 2018 |
Prescribing Patterns of Proprotein Convertase Subtilisin-Kexin Type 9 Inhibitors in Eligible Patients With Clinical Atherosclerotic Cardiovascular Disease or Heterozygous Familial Hypercholesterolemia.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Anticholesteremic Agents; Atherosclerosis; Cholesterol, LDL; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hyperlipoproteinemia Type II; Male; Middle Aged; PCSK9 Inhibitors; Practice Patterns, Physicians'; Retrospective Studies | 2018 |
Utilization Patterns of Lipid-lowering Therapies in Patients With Atherosclerotic Cardiovascular Disease or Diabetes: A Population-based Study in South Korea.
Topics: Aged; Anticholesteremic Agents; Atherosclerosis; Databases, Factual; Diabetes Mellitus; Drug Utilization; Ezetimibe; Female; Humans; Lipids; Male; Medication Adherence; Middle Aged; Republic of Korea; Retrospective Studies | 2018 |
The important role of apolipoprotein A-II in ezetimibe driven reduction of high cholesterol diet-induced atherosclerosis.
Topics: Animals; Animals, Genetically Modified; Anticholesteremic Agents; Apolipoprotein A-II; Atherosclerosis; Cholesterol; Diet, High-Fat; Endothelial Cells; Ezetimibe; Granulocytes; Hep G2 Cells; Hepatocyte Nuclear Factor 4; Hepatocytes; Humans; Hypercholesterolemia; Lipid Metabolism; Lipids; Macrophages; Microscopy, Confocal; PPAR alpha; THP-1 Cells; Zebrafish | 2019 |
Association of a Combined Measure of Adherence and Treatment Intensity With Cardiovascular Outcomes in Patients With Atherosclerosis or Other Cardiovascular Risk Factors Treated With Statins and/or Ezetimibe.
Topics: Aged; Anticholesteremic Agents; Atherosclerosis; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Medication Adherence; Middle Aged; Renal Insufficiency, Chronic; Retrospective Studies; Risk Factors | 2018 |
Simulation of the Impact of Statin Intolerance on the Need for Ezetimibe and/or Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor for Meeting Low-Density Lipoprotein Cholesterol Goals in a Population With Atherosclerotic Cardiovascular Disease.
Topics: Algorithms; Anticholesteremic Agents; Atherosclerosis; Atorvastatin; Cardiovascular Diseases; Cholesterol, LDL; Drug Therapy, Combination; Drug Tolerance; Ezetimibe; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; PCSK9 Inhibitors; Retrospective Studies | 2019 |
ETC-1002 (Bempedoic acid) for the management of hyperlipidemia: from preclinical studies to phase 3 trials.
Topics: Animals; Anticholesteremic Agents; Atherosclerosis; ATP Citrate (pro-S)-Lyase; C-Reactive Protein; Clinical Trials as Topic; Dicarboxylic Acids; Drug Therapy, Combination; Ezetimibe; Fatty Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Liver | 2019 |
Four Cases of Cholesterol Management Informed by the 2018 American Heart Association/American College of Cardiology Multisociety Guideline on the Management of Blood Cholesterol.
Topics: Adult; American Heart Association; Anticholesteremic Agents; Atherosclerosis; Cardiology; Cardiovascular Diseases; Cholesterol, LDL; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Practice Guidelines as Topic; Primary Prevention; Secondary Prevention; United States | 2019 |
2018 American Heart Association/American College of Cardiology/Multisociety Guideline on the Management of Blood Cholesterol-Secondary Prevention.
Topics: American Heart Association; Anticholesteremic Agents; Atherosclerosis; Cardiovascular Diseases; Cholesterol, LDL; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Medication Adherence; Patient Care Planning; PCSK9 Inhibitors; Practice Guidelines as Topic; Risk Reduction Behavior; Secondary Prevention; United States | 2019 |
Nonglucuronidated Ezetimibe Disrupts CD13- and CD64-Coassembly in Membrane Microdomains and Decreases Cellular Cholesterol Content in Human Monocytes/Macrophages.
Topics: Atherosclerosis; Biological Transport; CD13 Antigens; Cholesterol; Ezetimibe; Flow Cytometry; Glucuronates; Humans; Macrophages; Membrane Microdomains; Membrane Transport Proteins; Monocytes; Receptors, IgG | 2019 |
Hepatic Expression of Niemann-Pick C1-Like 1, a Cholesterol Reabsorber from Bile, Exacerbates Western Diet-Induced Atherosclerosis in LDL Receptor Mutant Mice.
Topics: Animals; Atherosclerosis; Cholesterol; Diet, Western; Disease Models, Animal; Ezetimibe; Hyperlipidemias; Intestinal Mucosa; Liver; Male; Membrane Transport Proteins; Mice; Mutation; Receptors, LDL; Up-Regulation | 2019 |
Residual inflammatory risk in coronary heart disease: incidence of elevated high-sensitive CRP in a real-world cohort.
Topics: Aged; Anti-Inflammatory Agents; Anticholesteremic Agents; Atherosclerosis; C-Reactive Protein; Cholesterol, LDL; Cohort Studies; Coronary Disease; Cross-Sectional Studies; Ezetimibe; Female; Humans; Incidence; Inflammation; Male; Natriuretic Peptide, Brain; Peptide Fragments; Retrospective Studies | 2020 |
Simulation of impact on cardiovascular events due to lipid-lowering therapy intensification in a population with atherosclerotic cardiovascular disease.
Topics: Aged; Angina, Unstable; Antibodies, Monoclonal, Humanized; Atherosclerosis; Cause of Death; Cholesterol, LDL; Cohort Studies; Elective Surgical Procedures; Ezetimibe; Female; Hospitalization; Humans; Hypolipidemic Agents; Insurance, Health, Reimbursement; Male; Medication Adherence; Middle Aged; Monte Carlo Method; Myocardial Infarction; Percutaneous Coronary Intervention; Proportional Hazards Models; Risk; Stroke | 2019 |
Characterization of the pharmaceutical effect of drugs on atherosclerotic lesions in vivo using integrated fluorescence imaging and Raman spectral measurements.
Topics: Animals; Anticholesteremic Agents; Atherosclerosis; Atorvastatin; Azetidines; Blood Vessels; Ezetimibe; Heptanoic Acids; Hypercholesterolemia; Lipid Metabolism; Lipids; Microscopy, Confocal; Pyrroles; Spectrum Analysis, Raman; Zebrafish | 2014 |
Endoplasmic reticulum stress effector CCAAT/enhancer-binding protein homologous protein (CHOP) regulates chronic kidney disease-induced vascular calcification.
Topics: Animals; Apolipoproteins E; Atherosclerosis; Azetidines; Calcinosis; Cardiovascular Diseases; Case-Control Studies; Drug Therapy, Combination; Endoplasmic Reticulum; Ezetimibe; Humans; Ketocholesterols; Lipids; Male; Mice, Inbred C57BL; Mice, Knockout; Middle Aged; Renal Insufficiency, Chronic; Simvastatin; Transcription Factor CHOP; Vascular Diseases | 2014 |
Trends in use of ezetimibe after the ENHANCE trial, 2007 through 2010.
Topics: Adolescent; Adult; Aged; Anticholesteremic Agents; Atherosclerosis; Azetidines; Clinical Trials as Topic; Disease Progression; Ezetimibe; Female; Humans; Hypercholesterolemia; Insurance, Pharmaceutical Services; Male; Middle Aged; Retrospective Studies; Simvastatin; Treatment Outcome; United States | 2014 |
High-intensity statin monotherapy versus moderate-intensity statin plus ezetimibe therapy: effects on vascular biomarkers.
Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Atherosclerosis; Azetidines; Biomarkers; Dose-Response Relationship, Drug; Drug Therapy, Combination; Endothelium, Vascular; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Randomized Controlled Trials as Topic | 2015 |
Splenic extrafollicular reactions and BM plasma cells sustain IgM response associated with hypercholesterolemia.
Topics: Animals; Anticholesteremic Agents; Apolipoproteins E; Atherosclerosis; Autoantibodies; Azetidines; Bone Marrow Cells; Cholesterol; Ezetimibe; Hypercholesterolemia; Immunoglobulin M; Lipoproteins, LDL; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Plasma Cells; Spleen | 2015 |
[Research advances on the therapeutic role of ezetimibe in atherosclerotic cardiovascular diseases].
Topics: Anticholesteremic Agents; Atherosclerosis; Ezetimibe; Humans | 2015 |
Ezetimibe Attenuates Atherosclerosis Associated with Lipid Reduction and Inflammation Inhibition.
Topics: Animals; Anticholesteremic Agents; Apolipoproteins E; Atherosclerosis; Cholesterol; Cytokines; Ezetimibe; Inflammation Mediators; Lipid Metabolism; Macrophages; Male; Mice; Mice, Knockout | 2015 |
Inhibition of macrophage-derived foam cell formation by ezetimibe via the caveolin-1/MAPK pathway.
Topics: Animals; Apolipoproteins E; Atherosclerosis; Caveolin 1; CD36 Antigens; Cell Line; Cholesterol; Diet, High-Fat; Ezetimibe; Foam Cells; Humans; Male; MAP Kinase Signaling System; Mice; Up-Regulation | 2016 |
Considerations in Applying the Results of Randomized Controlled Clinical Trials to the Care of Older Adults With Kidney Disease in the Clinical Setting: The SHARP Trial.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Anticholesteremic Agents; Atherosclerosis; Clinical Decision-Making; Drug Administration Schedule; Drug Therapy, Combination; Ezetimibe; Female; Health Services for the Aged; Humans; Male; Middle Aged; Practice Guidelines as Topic; Randomized Controlled Trials as Topic; Renal Dialysis; Renal Insufficiency, Chronic; Risk Factors; Simvastatin | 2016 |
Effect of ezetimibe plus pravastatin on endothelial dysfunction in patients with systemic lupus erythematosus.
Topics: Adult; Anticholesteremic Agents; Atherosclerosis; Brachial Artery; C-Reactive Protein; Cholesterol; Drug Therapy, Combination; Endothelium, Vascular; Ezetimibe; Female; Humans; Lupus Erythematosus, Systemic; Male; Middle Aged; Pravastatin; Ultrasonography; Vasodilation | 2016 |
Cost-effectiveness of PCSK9 Inhibitor Therapy in Patients With Heterozygous Familial Hypercholesterolemia or Atherosclerotic Cardiovascular Disease.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Anticholesteremic Agents; Atherosclerosis; Cardiovascular Diseases; Cholesterol, LDL; Cost-Benefit Analysis; Drug Costs; Ezetimibe; Female; Humans; Hyperlipoproteinemia Type II; Male; Middle Aged; Proprotein Convertase 9; Proprotein Convertases; Quality-Adjusted Life Years; Serine Endopeptidases; Uncertainty; United States | 2016 |
Statins, Ezetimibe, and Proprotein Convertase Subtilisin-Kexin Type 9 Inhibitors to Reduce Low-Density Lipoprotein Cholesterol and Cardiovascular Events.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Anticholesteremic Agents; Atherosclerosis; Cardiovascular Diseases; Cholesterol, LDL; Coronary Artery Disease; Dyslipidemias; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; PCSK9 Inhibitors; Practice Guidelines as Topic | 2017 |
The implications of the ezetimibe and simvastatin in hypercholesterolemia enhances atherosclerosis regression trial: a return to first principles.
Topics: Anticholesteremic Agents; Atherosclerosis; Azetidines; Cholesterol; Clinical Trials as Topic; Drug Therapy, Combination; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Simvastatin; Treatment Outcome | 2008 |
Is it over for ezetimibe?
Topics: Anticholesteremic Agents; Atherosclerosis; Azetidines; Controlled Clinical Trials as Topic; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Simvastatin | 2008 |
After ENHANCE: the cholesterol hypothesis is alive and well.
Topics: Anticholesteremic Agents; Atherosclerosis; Azetidines; Ezetimibe; Humans; Hypercholesterolemia; Randomized Controlled Trials as Topic; Simvastatin; Tunica Intima; Tunica Media; Ultrasonography | 2008 |
Is carotid intima-media thickness a reliable clinical predictor?
Topics: Anticholesteremic Agents; Atherosclerosis; Azetidines; Carotid Arteries; Carotid Artery Diseases; Coronary Disease; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Simvastatin; Tunica Intima; Tunica Media | 2008 |
Calcific aortic stenosis.
Topics: Animals; Anticholesteremic Agents; Aortic Valve Stenosis; Atherosclerosis; Azetidines; Calcinosis; Disease Progression; Ezetimibe; Humans; Models, Biological; Renal Insufficiency, Chronic; Simvastatin | 2009 |
Ezetimibe reduces plaque inflammation in a rabbit model of atherosclerosis and inhibits monocyte migration in addition to its lipid-lowering effect.
Topics: Animals; Anticholesteremic Agents; Atherosclerosis; Azetidines; C-Reactive Protein; Cell Line; Cell Movement; Chemokine CCL2; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Therapy, Combination; Ezetimibe; Femoral Artery; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Inflammation Mediators; Lipids; Macrophages; Male; Monocytes; NF-kappa B; Rabbits; Simvastatin | 2009 |
Vascular lipid accumulation, lipoprotein oxidation, and macrophage lipid uptake in hypercholesterolemic zebrafish.
Topics: Age Factors; Aging; Animals; Animals, Genetically Modified; Anticholesteremic Agents; Atherosclerosis; Azetidines; Cell Line; Cholesterol, Dietary; Disease Models, Animal; Endothelium, Vascular; Ezetimibe; Female; Green Fluorescent Proteins; Humans; Hypercholesterolemia; Larva; Lipid Metabolism; Lipoproteins; Luminescent Proteins; Macrophages; Male; Mice; Microscopy, Confocal; Oxidation-Reduction; Permeability; Phospholipases A2; Time Factors; Toll-Like Receptor 4; Zebrafish | 2009 |
The Zetia challenge: an update.
Topics: Anticholesteremic Agents; Atherosclerosis; Azetidines; Cardiovascular Diseases; Ezetimibe; Humans; Myocardial Infarction | 2009 |
Ezetimibe improves postprandial hyperlipidaemia in patients with type IIb hyperlipidaemia.
Topics: Anticholesteremic Agents; Atherosclerosis; Azetidines; Ezetimibe; Female; Humans; Hyperlipidemias; Japan; Lipoproteins; Male; Postprandial Period; Risk Factors; Triglycerides | 2009 |
High resolution magnetic resonance imaging in atherosclerotic mice treated with ezetimibe.
Topics: Animals; Anticholesteremic Agents; Aorta, Thoracic; Aortic Diseases; Apolipoproteins E; Atherosclerosis; Azetidines; Body Weight; Cholesterol; Disease Models, Animal; Ezetimibe; Magnetic Resonance Angiography; Mice; Mice, Inbred C57BL; Mice, Knockout; Reproducibility of Results; Time Factors | 2009 |
Ezetimibe - new anti-atherogenic properties?
Topics: Animals; Anticholesteremic Agents; Atherosclerosis; Azetidines; C-Reactive Protein; Cell Movement; Chemokine CCL2; Disease Models, Animal; Drug Therapy, Combination; Ezetimibe; Femoral Artery; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Inflammation Mediators; Lipids; Macrophages; Monocytes; NF-kappa B; Rabbits; Simvastatin | 2009 |
[Statin plus niacin or ezetimibe? What combination for which patients?].
Topics: Anticholesteremic Agents; Atherosclerosis; Azetidines; Carotid Artery Diseases; Coronary Disease; Drug Therapy, Combination; Ezetimibe; Humans; Hypolipidemic Agents; Niacin; Prospective Studies; Randomized Controlled Trials as Topic; Risk Factors; Time Factors | 2009 |
ARBITER 6-HALTS. Does it have the power to settle all matters?
Topics: Adult; Anticholesteremic Agents; Atherosclerosis; Azetidines; Drug Therapy, Combination; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Male; Niacin; Randomized Controlled Trials as Topic; Risk Factors | 2010 |
Therapy: raising HDL cholesterol levels: a flight of Icarus?
Topics: Atherosclerosis; Azetidines; Carotid Arteries; Cholesterol, HDL; Cholesterol, LDL; Clinical Trials as Topic; Ezetimibe; Humans; Niacin; Quinolines | 2010 |
The role of ezetimibe in the prevention of cardiovascular disease: where do we stand after ARBITER 6-HALTS.
Topics: Anticholesteremic Agents; Atherosclerosis; Azetidines; Cardiovascular Diseases; Carotid Arteries; Cholesterol, HDL; Cholesterol, LDL; Clinical Trials as Topic; Ezetimibe; Humans; Tunica Intima; Tunica Media | 2010 |
Managing residual risk in patients receiving statin therapy.
Topics: Anticholesteremic Agents; Atherosclerosis; Azetidines; Cholesterol, LDL; Ezetimibe; Humans; Hypercholesterolemia; Simvastatin | 2010 |
Vascular protective effects of ezetimibe: seeking new therapeutic possibilities of ezetimibe in vascular disease.
Topics: Anticholesteremic Agents; Atherosclerosis; Azetidines; Cardiovascular Diseases; Ezetimibe; Humans | 2011 |
Emphasizing the burden of proof: The American College of Cardiology 2008 Expert Panel Comments on the ENHANCE Trial.
Topics: Anticholesteremic Agents; Atherosclerosis; Azetidines; Biomarkers; Cardiology; Carotid Arteries; Clinical Trials as Topic; Clinical Trials Data Monitoring Committees; Evidence-Based Medicine; Expert Testimony; Ezetimibe; Humans; Hypercholesterolemia; Lipoproteins, LDL; Simvastatin | 2010 |
Another clinical evidence straw on the $4 billion ezetimibe camel's back.
Topics: Atherosclerosis; Azetidines; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Peripheral Arterial Disease | 2011 |
Management of familial hypercholesterolaemia in children and adolescents.
Topics: Adolescent; Anticholesteremic Agents; Atherosclerosis; Azetidines; Child; Child, Preschool; Cholesterol, LDL; Disease Management; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II | 2012 |
Ezetimibe ameliorates atherosclerotic and inflammatory markers, atherogenic lipid profiles, insulin sensitivity, and liver dysfunction in Japanese patients with hypercholesterolemia.
Topics: Administration, Oral; Anticholesteremic Agents; Asian People; Atherosclerosis; Azetidines; Biomarkers; Case-Control Studies; Ezetimibe; Female; Humans; Hypercholesterolemia; Inflammation; Insulin Resistance; Lipids; Lipoproteins, HDL; Lipoproteins, LDL; Liver Diseases; Male; Matrix Metalloproteinase 9; Middle Aged; Prognosis; Prospective Studies; Vascular Cell Adhesion Molecule-1 | 2012 |
Serendipity of post-hoc surrogate marker research.
Topics: Anticholesteremic Agents; Atherosclerosis; Azetidines; Cholesterol, LDL; Ezetimibe; Female; Humans; Male | 2012 |
Inhibition of intestinal cholesterol absorption decreases atherosclerosis but not adipose tissue inflammation.
Topics: Adipose Tissue; Animals; Atherosclerosis; Azetidines; Cholesterol; Ezetimibe; Immunohistochemistry; Inflammation; Insulin Resistance; Intestinal Absorption; Intestines; Macrophages; Mice; Mice, Inbred C57BL; Mice, Knockout; Real-Time Polymerase Chain Reaction; Receptors, LDL; Weight Gain | 2012 |
Ezetimibe inhibits PMA-induced monocyte/macrophage differentiation by altering microRNA expression: a novel anti-atherosclerotic mechanism.
Topics: Anticholesteremic Agents; Atherosclerosis; Azetidines; Cell Adhesion; Cell Culture Techniques; Cell Differentiation; Cell Line; Ezetimibe; Flow Cytometry; Humans; Macrophages; MicroRNAs; Monocytes; NF-kappa B; Reactive Oxygen Species; Real-Time Polymerase Chain Reaction; Tetradecanoylphorbol Acetate | 2012 |
Systems biology analysis unravels the complementary action of combined rosuvastatin and ezetimibe therapy.
Topics: Animals; Anticholesteremic Agents; Apolipoprotein E3; Atherosclerosis; Azetidines; Drug Therapy, Combination; Ezetimibe; Female; Fluorobenzenes; Mice; Mice, Transgenic; Pyrimidines; Risk Factors; Rosuvastatin Calcium; Sulfonamides; Systems Biology | 2012 |
Effect of ezetimibe on major atherosclerotic disease events and all-cause mortality.
Topics: Anticholesteremic Agents; Atherosclerosis; Azetidines; Cause of Death; Cholesterol, LDL; Coronary Artery Disease; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Michigan; Middle Aged; Odds Ratio; Retrospective Studies | 2013 |
Familial hypercholesterolaemia in children and adolescents: a new paediatric model of care.
Topics: Adolescent; Adult; Anticholesteremic Agents; Atherosclerosis; Azetidines; Child; Congenital Abnormalities; Coronary Stenosis; Disease Progression; Early Diagnosis; Ezetimibe; Female; Genetic Predisposition to Disease; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Male; Standard of Care | 2013 |
Arterial retention of remnant lipoproteins ex vivo is increased in insulin resistance because of increased arterial biglycan and production of cholesterol-rich atherogenic particles that can be improved by ezetimibe in the JCR:LA-cp rat.
Topics: Animals; Anticholesteremic Agents; Arteries; Atherosclerosis; Azetidines; Biglycan; Cholesterol; Ezetimibe; Insulin Resistance; Lipoproteins; Male; Metabolic Syndrome; Rats; Simvastatin | 2012 |
Effects of ezetimibe on atherogenic lipoproteins and glucose metabolism in patients with diabetes and glucose intolerance.
Topics: Aged; Aged, 80 and over; Anticholesteremic Agents; Atherosclerosis; Azetidines; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Ezetimibe; Female; Follow-Up Studies; Glucose Intolerance; Glycated Hemoglobin; Homeostasis; Humans; Japan; Lipoproteins, LDL; Male; Middle Aged; Risk Factors; Treatment Outcome; Weight Loss | 2013 |
Therapy and clinical trials.
Topics: Anticholesteremic Agents; Atherosclerosis; Azetidines; Clinical Trials as Topic; Ezetimibe; Humans; Hypercholesterolemia; Simvastatin | 2005 |
Ezetimibe inhibits the incorporation of dietary oxidized cholesterol into lipoproteins.
Topics: Absorption; Anticholesteremic Agents; Atherosclerosis; Azetidines; Cholesterol; Cholesterol, Dietary; Chylomicrons; Ezetimibe; Female; Humans; Lipids; Lipoproteins; Male; Oxygen; Postprandial Period; Time Factors | 2006 |
Therapy and clinical trials.
Topics: Acquired Immunodeficiency Syndrome; Atherosclerosis; Azetidines; Cholesterol, LDL; Clinical Trials as Topic; Ezetimibe; Humans; Hypercholesterolemia; Metabolic Syndrome; Models, Biological; Obesity; Risk Factors | 2007 |
Critical lessons from the ENHANCE trial.
Topics: Anticholesteremic Agents; Atherosclerosis; Azetidines; Carotid Arteries; Conflict of Interest; Data Interpretation, Statistical; Drug Approval; Drug Industry; Ezetimibe; Humans; Hyperlipoproteinemia Type II; Mass Media; Randomized Controlled Trials as Topic; Simvastatin; Ultrasonography | 2008 |
Mismanaged measures.
Topics: Atherosclerosis; Azetidines; Biomarkers; Cholesterol; Clinical Trials as Topic; Diabetes Mellitus; Ezetimibe; Humans; Reproducibility of Results; Treatment Outcome | 2008 |
After ENHANCE: is more LDL cholesterol lowering even better?
Topics: Anticholesteremic Agents; Atherosclerosis; Azetidines; Biomarkers; Carotid Artery Diseases; Cholesterol, LDL; Drug Therapy, Combination; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Inflammation; Lipid Metabolism; Simvastatin | 2008 |
The ENHANCE Study: an unusual publication of trial data raises questions beyond ezetimibe.
Topics: Anticholesteremic Agents; Atherosclerosis; Azetidines; Biomarkers; Cholesterol, HDL; Cholesterol, LDL; Controlled Clinical Trials as Topic; Drug Design; Dyslipidemias; Ezetimibe; Humans; Quinolines | 2008 |